DK150690B - Fremgangsmaade og analysepakke til bestemmelse af en komponent i reaktionen mellem et specifikt binder-protein og det tilsvarende bindelige stofved enzym-immunoanalyse - Google Patents

Fremgangsmaade og analysepakke til bestemmelse af en komponent i reaktionen mellem et specifikt binder-protein og det tilsvarende bindelige stofved enzym-immunoanalyse Download PDF

Info

Publication number
DK150690B
DK150690B DK639871AA DK639871A DK150690B DK 150690 B DK150690 B DK 150690B DK 639871A A DK639871A A DK 639871AA DK 639871 A DK639871 A DK 639871A DK 150690 B DK150690 B DK 150690B
Authority
DK
Denmark
Prior art keywords
enzyme
antibodies
reaction
specific binding
hcg
Prior art date
Application number
DK639871AA
Other languages
English (en)
Other versions
DK150690C (da
Inventor
Antonius Hermanus Wilh Schuurs
Bauke Klaas Van Weemen
Original Assignee
Organon Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organon Nv filed Critical Organon Nv
Publication of DK150690B publication Critical patent/DK150690B/da
Application granted granted Critical
Publication of DK150690C publication Critical patent/DK150690C/da

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743Steroid hormones
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • G01N33/539Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody involving precipitating reagent, e.g. ammonium sulfate
    • G01N33/541Double or second antibody, i.e. precipitating antibody
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/964Chemistry: molecular biology and microbiology including enzyme-ligand conjugate production, e.g. reducing rate of nonproductive linkage
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/971Capture of complex after antigen-antibody reaction
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/975Kit
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/807Apparatus included in process claim, e.g. physical support structures
    • Y10S436/808Automated or kit
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/815Test for named compound or class of compounds
    • Y10S436/817Steroids or hormones
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00Chemistry: analytical and immunological testing
    • Y10S436/815Test for named compound or class of compounds
    • Y10S436/817Steroids or hormones
    • Y10S436/818Human chorionic gonadotropin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Description

150690 ø
Det er kendt, at en komponent i reaktionen mellem et specifikt binderprotein og det tilsvarende bindelige stof kan bestemmes ved, at man inkuberer en af de omhandlede komponenter forsynet med en markør i en reaktionsblanding, som i det mindste indeholder den anden komponent, 5 og derpå iværksætter en adskillelse mellem den mærkede komponent, som henholdsvis er og ikke er bundet til dens bindingspartner og endelig bestemmer markøren i mindst en af de to fremkomne fraktioner. Fordelingen af den mærkede komponent over de to fraktioner er et mål for den mængde af den søgte komponent, som er til stede i prøven. Der 10 kan beskrives tre systemer, i hvilke den ovennævnte fremgangsmåde kan anvendes, a) antistoffer som specifikke binder-proteiner og de tilsvarende antigener som bindelige stoffer. Stoffer, som kan bestemmes 150690 . 2 på denne måde, er bl, a. proteinhormoner og deres antistoffer eller virus-antigener og deres antistoffer, b) antistoffer som specifikke binder-proteiner og haptener som bindeligt stof. Her defineres hap-tenerne som proteinfri stoffer, der kan reagere med antistoffer uden 5 at være i stand til at inducere dem. Stoffer, som kan bestemmes i et sådant system, er bl.a. steroidhormoner og vitaminer, c) proteiner, som i legemet virker som receptor- eller transport-molekyler som specifikke binder-proteiner og stoffer, som er bundet af dem som binde-lige stoffer. Dette system er f.eks. egnet til bestemmelse af ste-10 roidhormoner, men også af thyroxin og triiodthyronin, vitamin B12, den intrinsicole faktor og det adrenocorticotrope hormon.
De vigtigste punkter i de beskrevne analysemetoder er anvendelsen af en markør og adskillelsen af den mærkede komponent i en fraktion, 15 som er bundet, og en fraktion, som ikke er bundet til den tilsvarende komponent.
Fra beskrivelsen til dansk patentansøgning nr. 5462/71 kendes en fremgangsmåde, ved hvilken der anvendes enzymmærket komponent i forbindel-20 se med en kvantitativ immunologisk bestemmelse. Ved denne kendte fremgangsmåde sker adskillelsen mellem flydende og fast fase ved gelfiltrering, men denne metode er upraktisk og kan ikke give nogen pålidelig og let bestemmelse. Ved metoden kan immunokomponenter kun bestemmes i en koncentration på 50-100 nanogram pr. milliliter.
25
Fra beskrivelsen til dansk patentansøgning nr. 2812/67 kendes endvidere en fremgangsmåde, ved hvilken der gøres brug af uopløseliggjorte antistoffer overfor proteiner eller peptider, som er antigener, i en radio-immun bestemmelse. Radiaktive atomer anvendt som markører er 30 f.eks. 131j, 125^, 14^, 3^, 5?Co Denne fremgangsmåde er kendetegnet ved en høj følsomhed. Imidlertid er denne fremgangsmåde begrænset til institutter, hvor det nødvendige specielle apparatur er tilgængeligt.
Adskillelsesmetoderne kan opdeles på følgende måde: 35 a) Fremgangsmåder afhængige af forskellen i fysiske egenskaber mellem den ikke bundne, mærkede komponent og dens kompleks med bindings-partneren, såsom gel-filtrering, elektroforese, saltudfældning og absorption til dekstran-overtrukket trækul.
40 b. Den såkaldte fastfase-metode, ved hvilken den ene komponent allerede i forvejen er bragt i uopløselig form ved tværbinding eller ved 3 150690 covalent binding eller fysisk adsorption til en fast bærer, c) Den såkaldte dobbelte antistof«metode,ifølge hvilken det dannede kompleks, antigen (eller hapten)«antistof udfældes ved hjælp af antistoffer over for antistoffet i komplekset, hvilken fremgangsmåde 5 kun er kendt fra systemer, i hvilke antistoffer i opløst form kommer i betragtning«
Medens de under a) og c) omtalte fremgangsmåder er relativt komplicerede, lider de under b) omtalte af den ulempe, at en reaktions-10 komponent, når den bringes i uopløselig form, som regel vil mindske sin affinitet til reaktions-partneren. Imidlertid er en høj affinit« vigtig for tilvejebringelse af et følsomt prøvesystem.
Ifølge opfindelsen har man fundet en fremgangsmåde til bestemmelse 15 af en komponent i reaktionen mellem et specifikt binder-protein og det tilsvarende bindelige stof under anvendelse af den kendte bindingsaffinitet af sådanne komponenter indbyrdes, idet man ved bestemmelsen anvender en kendt mængde af et koblingsprodukt af det bindelige stof med et enzym og eventuelt også en kendt mængde af det 20 specifikke binderprotein (i det tilfælde, at det bindelige stof er den komponent, der skal bestemmes), hvilken fremgangsmåde er ejendommelig ved, at man yderligere anvender . uopløseliggjo.rte antistoffer oVér for det-< specif ikke binder-protein,·' og at man efter reaktionen bestemmer enzymaktiviteten i den flydende eller 25 faste fase af reaktionsblandingen. Denne fremgangsmåde muliggør bestemmelse af komponenter, der er til stede i en koncentration på 1-1C nanogram pr. milliliter.
I den foreliggende beskrivelse bruges begreberne conjugat og enzym-30 conjugat synonymt for koblingsproduktet af det bindelige stof og enzymet.
Det bindelige stof kan opdages og bestemmes ved, at man sammenbringer den ukendte prøve eller en fortyndingsserie af samme med en kendt 35 mængde af et conjugat af det stof, der skal bestemmes, og et enzym og med en mængde specifikt binderprotein i afhængighed af den mængde enzym-conjugat, som tilsættes. Derpå tilsættes en mængde, fortrinsvis et overskud af de antistoffer, der er gjort uopløselige over for det specifikke binder-protein, så at hele enzym-conjugatet, som har 40 reageret med binder-proteinet, ved hjælp af dette protein bliver koblet til disse uopløselige antistoffer. Jo mere bindeligt stof der ex 4 150690 til stede i prøven, jo mindre enzym-conjugat vil reagere med det specifikke binder-protein og sluttelig komme i den uopløselige fase. Resultatet bliver, at mere ubundet enzym-conjugat forbliver i den flydende fase og på simpel måde kan bestemmes der. Det specifikke 5 binder-protein kan bestemmes ved, at man inkuberer prøven eller fortyndingsserier af denne med en kendt mængde enzym-conjugat og med en mængde af de over for det specifikke binder-protein uopløselig-gjorte antistoffer. Enzymaktiviteten kan kun finde sted i den uopløselige fase, hvis conjugatet har reageret med det specifikke bin-10 der-protein, d.v.s. jo mere specifikt binder-protein, der er i prøven, jo mindre bundet enzym-conjugat vil forblive i den flydende fase.
Den beskrevne analyse-metodes følsomhed kan varieres ved at ændre mængderne af reagenserne. Imidlertid er den mængde enzym-conjugat, 15 som kan anvendes, begrænset nedefter af kravet om, at dets enzymaktivitet kan måles på rimelig måde, hvorfor analyse-metodens følsomhed har sin begrænsning. Den minimalt målelige enzym-aktivitet er bl. a. afhængig af naturen af det enzym, der anvendes ved koblingen, og af substratets natur og endelig af enzym-reaktionens 20 inkubationstid. Fremdeles indvirker det specifikke binder-proteins affinitet stærkt på bestemmelsens følsomhed. Ved en analyse-metode af høj følsomhed kræves specifikke binder-proteiner med en høj affinitet.
25 Mængderne af de for en bestemmelse nødvendige reagenser må fastlægges ad empirisk vej.
Til bestemmelsen af det bindelige stof må mængden af enzym-conjugatet bestemmes ved hjælp af enzymaktiviteten. Derpå inkuberes denne mængde 30 med en fortyndingsserie af det specifikke binder-protein til bestemmelse af den nødvendige mængde af dette protein. Fortrinsvis vælger man en mængde specifikt binderprotein, som kan binde 50-90% af enzym-conjugatet. Til sidst undersøger man, hvorvidt den ønskede følsomhed så er blevet nået, idet man undersøger en fortyndingsserie af 35 det stof, der skal undersøges ved metoden.
Til bestemmelsen af det specifikke binder-protein må der angående doseringen af enzym-conjugatet tages hensyn til dettes aktivitet, som skal kunne bestemmes med rimelig nøjagtighed.
s 150690
De antistoffer over for det specifikke binder-protein, der er gjort uopløselige, tilsættes fortrinsvis i overskud ved de to bestemmelses-måder. Disses dosering bestemmes ved forudgående forsøg.
5 Denne fremgangsmådes fordele over for de kendte er, at kombinationen af "Dobbelt Antistof" og "Fast Fase"-metoden, i det følgende af bekvemmelighedsgrunde betegnet DASP-metoden, frembyder adskillige fordele over for de kendte fremgangsmåder. Således er udførelsen af den nye fremgangsmåde, d.v.s. tilførsel af uopløseliggjorte anti-10 stoffer over for det specifikke binder-protein, inkubation, centrifugering og måling, meget simpel, doseringen er ofte lettere end ved fast-fase-metoderne, fordi det er tilstrækkeligt at tilsætte et overskud af uopløst materiale, hvorimod man ved fast-fase-metoderne skal bruge en nøjagtigt udmålt mængde af det faste materiale. Frem-15 deles er affiniteten hos binder-proteinet til det bindelige stof ikke svækket af bindingen til bærermaterialet, således som det kan være tilfældet ved fast-fase-metoden. En yderligere fordel over for den sidste fremgangsmåde er den hurtige ligevægt-indstilling hos reaktionen mellem det specifikke binder-protein og det bindelige stof 20 (begge i opløsning). En yderligere fordel består i, at ved DASP- fremgangsmåden kan det uopløseliggjorte antistof, nedenfor betegnet immunoadsorbenten, bruges i ethvert system, i hvilket man bruger antistoffer som specifikke binder-proteiner, forudsat at disse antistoffer er præpareret i de samme dyrearter. På den anden side, for 25 ethvert antigen eller hapten, der skal bestemmes efter fast-fase-metoden, skal antistofferne gøres uopløselige. Den dobbelte antistofmetode er meget følsom over for relativt små ændringer i saltkoncentrationerne, pH og lignende, som gør en vidtgående kontrol af betingelserne nødvendig. Yderligere kræver metoden tilføjelse af 30 "bærer"-γ-globulin og følgelig meget andet antistof til opnåelse af et immunt precipitat. Foruden at være en mere enkel fremgangsmåde fører DASP-metoden, som ikke kræver "bærer"-γ-globulin, til besparelse af materialer. Endelig skal det nævnes, at en dobbelt antistoflignende adskillelse anvendt ved transport- eller receptor-proteiner 35 ikke er mulig, da der ikke kan fremskaffes et "bærer"-protein til dette formål. Fremgangsmåden ifølge opfindelsen frembyder derfor en enestående lejlighed i denne henseende.
Fremgangsmåden ifølge opfindelsen kan let gøres automatisk. Det er 40 principielt muligt at bringe reaktionskomponenterne sammen straks _ t t _ . i _ j . _ -? , » t_ _ i i ^ ^___ ^ r Λ__i · T __ __ i i____ 6 150690 man dog fortrinsvis de uopløselige antistoffer over for det specifikke binder-protein til reaktionsblandingen som det sidste reagens, idet det har vist sig, at bestemmelsen derved får en højere følsomhed.
5
Ved fremgangsmådens anvendelse til bestemmelse af det bindelige stof går man af samme grund hensigtsmæssigt frem på den måde, at man først til prøven sætter det specifikke binder-protein og derpå enzym-con-jugatet og til sidst de uopløselige antistoffer over for det speci-fikke binder-protein.
Det for opfindelsen nødvendige reagens, d.v.s. koblingsproduktet af antigen, hapten eller det bindelige stof med enzymet, kan fremstilles på kendt måde. Disse fremgangsmåder kan også bruges til at bin-15 de et hapten eller et lavmolekulært bindeligt stof til et enzym, forudsat at et af stofferne har en eller flere aminogrupper og det andet en eller flere carboxylgrupper. Hvis det sidste ikke er tilfældet, er det muligt at indføre den ønskede gruppe i molekylet, som skal kobles, ved hjælp af en kendt organokemisk proces. Der kendes 20 også fremgangsmåder til sammenbinding af amino- og carboxylgrupper, eventuelt ved at indføre en bro. Endelig kan komponenter som glutar-aldehyd, difluordinitrodiphenylsulfon og di- og tri-chloro-s-tria= zin ofte anvendes til den omhandlede kobling. Det kan blive nødvendigt at adskille de fremstillede enzymconjugater fra uomdannede stof-25 fer og fra stoffer, som er blevet inaktive. Til dette formål kan man benytte kendte fremgangsmåder, såsom udfældning med organiske opløsningsmidler, gelfiltration og centrifugering ved en vægtfyldegradient .
20 Valget af det enzym, der benyttes i koblingsproduktet, er bestemt ved et antal egenskaber hos enzymet. Naturligvis er det vigtigt, at enzymet er resistent over for koblingen med et andet molekyle, d.v.s. over for ændring af en eller flere aminosyre-sidekæder. Enzymets specifikke aktivitet er også af stor vigtighed. Da en mindre mæng-25 de enzym—conjugat behøver at tilføjes for at opnå en målelig enzympåvirkning, bliver undersøgelsessystemet mere følsomt. Fremdeles bør man foretrække de enzymer, hos hvilke en bestemmelse af aktiviteten kan foretages på en simpel måde, I første række bør man tage de enzymer i betragtning, for hvilke aktiviteten kan béstemmes kolorime-40. trisk, épektrofotometrisk eller fluorimetrisk. Sådanne bestemmelser 7 150690
Man kan bestemme aktiviteten af de, .enzymer kolorimetrisk, som katalyserer en reaktion, ved hvilken der. .opstår eller forsvinder et farvet stof, enten ved den primære eller den sekundære reaktion.
5 Som enzymer, der- kan" anvendes som den enzymatisk; aktive komponent i conjugater, skal nævnes catalase, peroxidase (3-glucoronidase, β-D-glucosidase, β-D-galactosidase, urease, glucose-oxidase, galactose-oxidase og alkalisk phosphatase.
10 Ved afslutningen af reaktionen mellem komponenterne og reagenserne kc man ifølge opfindelsen bestemme enzymaktiviteten i den flydende ellei den faste fase, eller i begge faserne af reaktionsblandingen. Det simpleste er imidlertid at bestemme enzymaktiviteten i den flydende fase, 15
De antistoffer, der er gjort uopløselige over for de specifikke binde proteiner, som også er vigtige reagenser for fremgangsmåden ifølge op findelsen, kan også fremstilles på kendt måde. Antistofferne kan fremstilles, idet man tager et renset præparat af det specifikke bin-20 der-protein eller af de proteiner, som har i det mindste delvis de sa me antigen-egenskaber som det specifikke binder-protein, og så injice rer dette på kendt måde i en anden dyreart end den, fra hvilken man fik det. Det behandlede dyrs serum eller gamma-globulin-fraktionen af dette kan gøres uopløseligt ved kryds-led-forbindelse med sådanne sto 25 fer som glutaraldehyd og chlormyresyre-ethylester eller ved binding t faste bærerpartikler enten fysisk eller adsorptivt eller kemisk ved dannelse af covalente bindinger. Som faste bærere kan anvendes sådanm stoffer som cellulose (ændret eller ikke), agarose, kryds-led-forbundi dekstran, polystyren og lignende. En covalent binding til disse stof· 30 fer af antistoffer kan foretages ved hjælp af sådanne stoffer som car: bodiimider, di- og tri-chloro-s-triaziner, glutaraldehyd, cyanogenbro-mid og f.eks. ved diazotering.
Fordelene ved fremgangsmåden ifølge opfindelsen til bestemmelse af 35 binderprotein opnås, hvis man anvender et overskud af uopløselige ant: stoffer, således at det specifikke binderprotein går helt over i den faste fase.
De former, i hvilke reagenserne kan anvendes, er mangfoldige. Den 40 enzym-conjugerede komponent i reaktionssysternet kan frysetørres eller 8 150690 opløses i en stødpude. Man kan også bruge en fast bærer, f,eks. en papirstrimmel imprægneret med conjugatet. Denne anvendes også til de nødvendige binder-proteiner.
Den uopløselige komponent kan bringes i form af partikler af forskellig størrelse, såsom granuler, flager, stave eller i form af en strimmel af et eller andet bæremateriale.
Opfindelsen angår endvidere en analysepakke til bestemmelse af * et specifikt binder-protein eller det tilsvarende bindelige stof ved den beskrevne fremgangsmåde, hvilken analysepakke er ejendommelig ved at den hovedsagelig indeholder: a) en kendt mængde conjugat af det bindelige stof og et enzym, ’ b) en kendt mængde binder-protein, hvis analysepakken skal anvendes til bestemmelse af det bindelige stof, c) én kendt mængde uopløseliggjorte antistoffer rettede imod det binderprotein, som er tilsat, eller som skal bestemmes, d) et substrat til bestemmelse af aktiviteten af det anvendte enzym.
i
Analysepakken kan fremdeles indeholde de nødvendige yderligere midler til analysens udførelse, såsom reagensglas, pipetter og flasker med opløsninger.
Analysepakken kan særlig hyppigt og med særlig fordel anvendes til opdagelse og bestemmelse af et antigen eller et hapten, og til dette formål indeholder den i hovedsagen: a) en kendt mængde af et conjugat af antigenet eller haptenet og et enzym, b) en tilsvarende mængde af tilsvarende antistoffer, c) en kendt mængde uopløseliggjorte antistoffer, rettede imod de anvendte antistoffer, d) et substrat til bestemmelse af aktiviteten af det anvendte enzym.
Når man anvender sådanne analysepakker til påvisning og bestemmelse af antistoffer, behøver man ikke de under b) nævnte antistoffer.
150690 9
En vigtig udførelsesform for en analysepakke ifølge opfindelsen er én ana-lysepakke til bestemmelse af de gonadotrope hormoner og særlig til bestem' melse af HCG (Human Chorionic Gonadotropin) som et middel til bestemmelse 5 af graviditet allerede på et meget tidligt stadium, hvilken analysepakke er ejendommelig ved, at den består af en beholder, der som væsentlige bestanddele i lyofiliserede lag indeholder: a) en bestemt mængde af et HCG-conjugat og et enzym, f.eks. HCG-peroxidase b) en bestemt mængde anti-HCG, c) en bestemt mængde uopløseliggjorte antistoffer oyer for anti-HCG sammei med et substrat til bestemmelse af enzymaktiviteten af det resterende HCG-enzym i den flydende fase.
Ved tilsætning af en vis mængde urin fra en formodet gravid kvinde, til 15 denne analyseblanding og ved at inkubere urinen med disse bestanddele dannes der en blanding af uopløseligt stof, idet den øvrige del indeholder det tilbageblevne opløselige HCG-enzym-conjugat. Mængden af det sidste afhænger af mængden af HCG i den undersøgte urin. Ved bestemmelse af enzymaktiviteten hos dette tilbageblevne HCG-enzym-conjugat kan man 20 fastslå, om urinen skyldes en gravid kvinde eller ej.
En fremgangsmåde, der fortrinsvis anvendes ved bestemmelsen af enzymaktiviteten, består i, at man bringer et indikator-papir imprægneret med enzymreagenser, f.eks, hvis der bruges en peroxidase, en H„09-forsyner så- 25 ^ ^ som urinstof-EL^,med et farvereagens såsom o-tolidin.
Ved korrekt valg af mængderne af hvert af reagenserne bliver det muligt at fastslå graviditet allerede på et meget tidligt stadium og på en simpel, hurtig og meget pålidelig måde, som kan udføres af en ikke opøvet 30 person.
150690 10
Eksempel 1.
Bestemmelse af det menneskelige chloriongonadotropin (HCG).
5 a) Fremstilling af HCG-HRP.
5 mg HCG og 20 mg peberrods-peroxidase (HRP) opløses i 2 ml 0,05 M phosphat-stødpude med pH-værdien 6,2. Efter tilsætning af ko μΐ 25$ glutaraldehyd-ορløsning rystedes “blandingen i 2 timer ved stuetemperatur. Efter 5 minutters centrifugering ved 250 g fraktioneredes væsken over Sephadex G-200 i 0,05 M phosphat= stødpude med pH-værdien 6,2. Fraktionerne, hos hvilke den højeste enzymaktivitets $ var bundet af antistoffer overfor HCG brugtes under analysen.
15 b) Fremstilling af antistoffer overfor HCG.
Antistoffer overfor HCG indiceredes i kaniner som angivet af Schuurs et al. Acta Endocr. (Kbh) 59j 120,(1968).
c) Fremstilling af antistoffer overfor kanin-y-globulin.
2q Kanin-Y-globulin isoleredes fra normalt kanin-serum ved udfældning med l8$ w/v fast natriumsulfat. Antistoffer overfor dette fremstilledes ved immunisering af et får i overensstemmelse med følgende skemai 25 dag mængde Freud's adjuvans injektionsmåde 0 o,5 mg + intramuscular 1^· o,5 mg + intramuscular 28 1 mg + intramuscular b2 1 mg - intravenøs 3Q 56 1 mg - intravenøs den 70.dag blev fåret åreladt.
d) Fremstilling af immunoadsorbent-eellulose /får-anti-(kanin-γ-globu= 35 lin)7.
γ-globulinfraktionen af fåre-serumet beskrevet under c) fremstilledes ved udfældning med 165¾ w/v fast natriumsulfat. Efter vaskning optoges udfældningen i så meget 0,05 M borat-stødpude med pH-værdien 8,6, at den fremkomne proteinkoncentration udgjorte 10 mg/ml.
4Q 350 mg m-aminobenzyloxymethylcellulose opslemmedes i 50 ml destilleret 11 15069¾ vand og diazoteredes ved tilsætning af 10 ml 30$ saltsyre og dråbevis tilsætning af 10 ml 10$ NaDiK^-opløsning ved 0°C. Op-slemningen centrifugeres. Den vaskedes, og bundfaldet resuspendere-des i *+3 ml 0,05 M natriumborat med pH-værdien 8,6, derpå tilsattes 5 7 ml af den fremstillede γ-globin-opløsning. Blandingen omrørtes i 26 timer ved å-°C, hvorpå den centrifugeredes og vaskedes med 0,02 M phosphat-stødpude med pH-værdien 6,0.
e) Bestemmelse af HCG
10 Der fremstilledes en fortyndingsserie (32 -16-8-^-2-1-o,5-IU/ml) af HCG i 0,02 M phosphat-stødpude med pH-værdien 6,0, som indeholdt 2$ v/v normalt fåreserum.
0,5 ml af hver af de HCG-indeholdende prøver inkuberedes med 0,1 ml kanin-(anti-HCG)-serum og 0,1 ml HCG-KRP-conjugat, begge i passen-15 de fortynding i eii halv time’ved stuetemperatur. Derpå tilsatte 0,3 ml af immunoadsorbenten (10 mg/ml) fremstillet ifølge d),og den fremkomne blanding omrørtes i en time ved stuetemperatur. Efter centrifugering bestemtes enzymaktiviteten: resten ved at blande 0,5 ml .
af denne væske med 1,5 ml substrat (10μ1 30$ ^.$2 °& 20 mg 5-amino--20 salicylsyre i 150 ml 0,02 M phosphatstødpude med pH-værdien.6,0), og efter 30 minutter ved 25°C måltes ekstinctionen ved 1+60 mm.
På denne måde påvistes det, at det var muligt at opdage en HCG-koncentration fra 0,5 til lIU/ml i prøven. Ved denne metode kunne man også undersøge urinprøver. Undersøgelsen er derfor egnet til 25 en graviditetsprøve. Forholdet til en eksisterende undersøgelsesmetode, en hæmaglutinations-·inhibitions-prøve var god. Det påvistes muligt at forøge systemets følsomhed ved anvendelse af en pre-incubation. Her incubereres prøven først med antiserumet og derpå tilsattes HCG-HRP-conjugatet.
30
Eksempel II.
Bestemmelse af insulin og anti-insulin.
a) fremstilling af insulin-(glucose-oxidase).
35 Der opløstes 5 mg grise-insulin af 25 mg glucose-oxidase i 2 ml 0,05 M phosphat-stødpude med pH-værdien 6,5. Hertil sættes 5 μΐ glutaraldehyd-opløsning, hvorefter blandingen rystedes i 90 minutter ved stuetemperatur. Blandingen fraktionereres over Sephadex 150690 12 G-200 i 0,05 M phosphat-stødpude med pH-værdien 6,5.De .fraktioner, af hvilke den højeste procentiske enzym-aktivitet kunne hindes af antistoffer overfor insulin, anvendtes ved analysen 5 b) Fremstilling af antistoffer overfor insulin.
Man ggv·' 10 marsvin &n;- ugentlig intramuskulær injektion med 1 mg grise-insulin i fuldstændig Freud's adjuvans gennem en periode på ^+-8 uger. Efter 10 ugers hvile gav man dyrene yderligere 1 mg insulin ved intravenøs injektion uden adjuvans. To uger senere blev 10 dyrene åreladt. Man modarbejdede den tilstødende hypoglycæmi ved intraperional administration af glucose.
c) Fremstilling af antistoffer ' overfor. maxsvin-γ-globulin.
Der . fremstilledes marsvin-Y-globulin ved tilsætning af 1 15 volumen ^mættet ammoniumsulfat-opløsninq til 2 volumen marsvine- serum. Den fremkomne udskillelse vaskedes to gange med 33i° mættet ammoniumsulfat-opløsning, hvorefter den optoges i en fysiologisk saltopløsning. Derpå immuniseredes et får med voksende doser af det fremstillede γ-globulin: 0,5 - 1 og 2 mg. Injektionerne blev 20 givet hver anden uge, idet immunogenet var blandet med fuldstændig
Freud's adjuvans. To uger efter den sidste injektion gaves der yderligere 2 mg γ-globulin i en fysiologisk saltopløsning, og en uge senere blev dyret åreladt.
25 d) Fremstilling af uopløselige antistoffer overfor marsvin-Y-globulin.
10 g mikrokrystallinsk cellulose aktiveredes ved, at det under omrøring sattes til H00 ml 2,5$ w/v CWBr-opløsning, hvorefter pH-værdien øgedes til 10,5 nied 1 N NaOH-opløsning, idet denne værdi opret 30 holdtes i 2 minutter. Derpå vaskedes cellulosen med isvand og med 0,1 M NaHCOy Der tilsattes 1,6 g Na^SO^ til 10 ml fåre-anti( marsvin.-γ-globulin) -serum. Efter en times omrøring ved stuetemperatur centrifugeres udfældningen. Der vaskedes to gange med 20 ml 16$ w/v Na^O^-opløsning, hvorefter det optoges i 10 ml 0,1 M NaHCO^-35 opløsning. Den aktiverede cellulose blandedes med *+0 ml 0,1 M NåKCO^- opløsning og de 10 ml γ-globulin-opløsning. Denne suspension om-rørtes i ^0 timer ved ^°0 og vaskedes efterhånden to gange med 150690 13 500 ml 0,5 M NaHCO^j to gange med 500 ml 0,05 M citrat af pH-værdien 1,1 og to gange med 500 ml 0,05 M phosphat af pH-værdien 6?5 5 e) Bestemmelse af antistoffer overfor insulin.
0,1 ml insulin-(glucose-oxidase) inkuberedes i passende fortynding med 0,*+ ml af en fortynding s serie af en marsvin-anti-insulin-serum i timer. Fortynding s s er i en foretoges med 0,05 M phosphat-stødpude med pH-værdien 6,0. Derpå tilsattes 0,3 ml immunoadsorbent 10 (15 mg/ml) og 0,2 ml stødpude, og blandingen omrørtes natten over ved *f°C. Efter centrifugering bestemtes enzymaktiviteten'af den resterende opløsning ved incubering af 0,5 ml af denne med 2,5 ml substrat i 30 minutter, hvorpå man målte ekstinetionen ved *+60 nm. Substratet indeholdt 50 mg glucose, 10 μg peroxidase og 1 mg 15 5- amino salicyl syre pr. 2,5 ml 0,05 M phosphat-stødpude med pH-værdien 6,0.
Med dette system kunne antistofindholdet i de forskellige slags serum sammenlignes. Som referencepunkt valgtes den serumfortynding, hvor 5o5 af den totale kombinerbare enzymaktivitet er bundet.
20 f) Bestemmelse af insulin.
0,2 ml af en fortyndingsserie af insulin incuberedes i 2 timer med 0,1+ ml anti-insulin-serum i en sådan fortynding, at den kunne binde 60$ af det tilsatte enzym-conjugat. Derpå tilsattes 0,1 ml 25 insulin-(glucose-oxidase) · des i timer. Endelig tilsattes 0,3 ml immunoadsorbent (15 mg/ml). Blandingen omrørtes natten over ved H°C. Efter centrifugering måltes enzymaktiviteten i resto. løsningen som angivet under e). Bestemmelsens følsomhed, som afhænger af det anvendte antiserum, lig-30 ger indenfor nanogram-ordenen: 20-100 mg/ml, d.v.s* 0,5-2,5 mU/ml.
Eksempel III.
Bestemmelse af oestradiol.
35 a) Fremstilling af oestradiol-17-succinyl-HRP.
50 mg oestradiol-17-hemisuceinat og 0,08 ml tri-n-butylamin opløstes i 2,5 ml dioxan. Til den kolde (2°C) opløsning sattes 15 Hl isobutylchlorocarbonat. Efter 3o minutter blandedes denne opløsning
lif T5069Q
med 100 mg peberrodsperoxidase (HRP) i 7?5 ml af en dioxan/vand-blanding (2:3)5 som var indstillet til en pH-værdi på 9j5 med natriumhydroxid. Opløsningen omrørtes i *+ timer ved 2°C og dialyseredes derpå i 18 timer. Udfældningen, der var dannet efter at dialysatets 5 pH-værdi var indstillet til *+,6, centrifugeredes fra, vaskedes og op toges i 5 ml destilleret vand, som var indstillet til en pH-værdi på 8. Stoffet rensedes yderligere ved to ganges udfældning med 10 ml acetone. Det færdige produkt optoges i 10 ml 0,05 M piiospliat-stødpude med pH-værdien 738.
10 b) Fremstilling af østradiol-17-suecinyl-BSA.
Fremstillingen foretoges ifølge den blandede anhydrid-metode, som er angivet i eksempel Illa. Denne fremstilling foretoges, idet man gik ud fra 100 mg østradiol-17-hemisuccinat og 150 mg hornkvægsse-15 rum-albumin (BSA).
c) Fremstilling af antistoffer overfor østradiol.
Man injicerede et får en gang i *+ uger med k mg østradiol-17-succinyl-BSA i fuldstændig Freund's adjuvans. Med regelmæssige mellem 20 rum udtoges der blod fra dyret. Serumet absorberedes med BSA, som var gjort uopløseligt.
d) Fremstilling af antistoffer overfor fåre-Y-globulin.
Der fremstilledes fåre-Y-globulin som angivet i eksempel I, men nu 25 med 16$ w/v natriumsulfat. Man immunicerede så kaniner med denne fåre-Y-globulin efter følgende skema:
Dag mængde Freund's ad.iuvans innektionsmåde 0 200 ^g + intramuskulær 30 lb *+00 μg + ' " 28 800 μg + " b2 800 ug - intravenøs o c 2 Uger efter den sidste injektion blev dyret åreladt.
i5 150690 e) Fremstilling af immunoadsorbenten /kanin-anti (-fåre-Y-globulin)_7-cellulose.
Y-Globulinfraktionen fra de antisera, der er angivet under d), fremstilledes ved udfældning med 18$ w/v Wa^SO^. Det fremkomne produkt 5 kobledes med cellulose efter Gurvich's metode, angivet i eksempel I.
f) Bestemmelse af østradiol.
Immunreaktionen udførtes i 0,02 M phosphat-stødpude med pH-værdien 6,0, som indeholdt 2$ BSA.
10 5 ml af prøven blandedes med 0,1 ml af fåre-anti-østradiolserumet i den ønskede fortynding. Efter 30 minutters inkubation ved stuetemperatur tilsattes 0,1 ml østradiol-17-succinyl-HRP i en passende fortynding, hvorefter der fulgte en anden 30 minutters inkubation 15 ved stuetemperatur. Derpå tilsattes Qf3 ml immunoadsorbent"su" spension (30 mg/mll, og blandingen omrørtes i 2 timer ved stue" temperatur. Derpå adskiltes den flydende og den faste fase ved centrifugering. Enzymaktiviteten i den flydende bestanddel måltes som angivet i eksempel I. Man kunne anvende fåre-anti-østradiol-20 serumet i fortyndinger fra 1:1600 til 1:12800 i afhængighed af kva liteten af det anvendte østradiol-17-succinyl-HRP. Ved en fortynding af 1:12800 af antiserumet kunne en østradiol-koncentration på 10 ng/ml opdages i prøven. Østradiol og østron viste en krydsreaktion i dette system.
25
Eksempel IV
Bestemmelse af cortisol og corticoid-bindende globulin.
a) Fremstilling af cortisol-21-(galaktose-oxidase).
30 Man koblede 50 mg cortisol-21-hemisuccinat og 100 mg galaktose- oxidase ved hjælp af den blandede anhydrid-teknik angivet i eksempel Illa.
b) Corticoid-bindende globulin (CBG) isoleredes fra human serum ved 35 hjælp af successions-kromatografi over DEAE-cellulose og hydroxyl- apatit.
Antistoffer overfor dette fremstilledes ved injicering af kaniner i 1^—dagesmellemrum med 500 Pg CBG i fuldstændig Freund's adjuvans.
Efter 3 måneder injiceredes dyrene med 1 mg CBG, og 2 uger senere i6 150690 c) γ-Globulin- fraktionen af anti-CBG- serum koblede s til m- aminobenzy1= oxymethylcellulose som angivet i eksempel III.
d) Bestemmelse af cortisol.
5 0,5 nil af en prøve, der indeholdt cortisol (standard-opløsning) ekstraheredes med 2 x 3 nil methylenchlorid. Den sammenbragte ekstraktionsvæske inddampedes til tørhed. Residuenten optoges i 0,5 ml 0,05 M phosphat-stødpude med pH-værdien 6,2. Derpå blandedes med 0,1 ml af en opløsning af CBG i den samme stødpude i en passende 10 koncentration, og der inkuberedes i 30 minutter ved h°C. Derpå tilsattes 0,1 ml cortisol-21-(galaktose-oxidase), også i passende fortyndingjOg 0,3 ml af immunoadsorbenten, der fremstilledes under c), med en koncentration af 5 mg/ml. Den fremkomne blanding omrør-tes i 2 timer ved ^°0 og derpå centrifugeredes, hvorefter enzymakti-15 viteten måltes i restvæsken. I den anledning tilsattes 0,5 nil af samme til 1,5 ml substrat bestående af 100 mg D-galaktose, 20 mg 5-aminosalicylsyre og 10 Mg peroxidase i 150 ml 0,02 M phosphat-stødpude med pH-værdien 6,0. Efter 30 minutter måltes ekstinctionen ved *+60 nm. Ved anvendelse af en CBG-koncentration på O,1* Mg/ml og 20 'så meget cortisol-21-(galaktose-oxidase), at 80$ af enzym-konjugatet var bundet til immunoadsorbenten, uden at der tilføjedes steroider, viste det sig muligt at bestemme mængder af fra 3 til 30 ng cortisol e) Bestemmelse af CBG var også mulig med de angivne reagenser. Fra en 25 fortyndingsserie af transcortin, rækkende fra O til 1280 ng/ml in kuberedes 0,5 ml i 15 minutter med 0,2 ml cortisol-21-(galaktose-oxidase) i passende fortynding. Derpå tilsattes 0,3 ml immunoad-sorbent-suspension (5 mg/ml), og blandingen omrørtes i 15 minutter. De to inkubationer holdtes ved Η-°ϋ. Derpå måltes enzymaktiviteten 30 i restvæsken som under d) c Analysemetodens følsomhed viste sig at være 50 ng/ml).
Eksempel V
35 I en flaske lyofiliseredes efterhånden følgende reagenser i adskilte lag: 0,3 ml af immunoadsorbent-suspensionen (10 mg/ml) som angivet i eksempel la.
40 2) 0,1 ml af en Ifo mannitol-opløsning.

Claims (2)

17 150.690 3) 0,1 nil af HCG-HRP som angivet i eksempel la. et andet lag af 0,1 ml af en 1} mannitol-opløsning. 5) 0,1 ml af kanin(anti-HCG)-serum som angivet i eksempel II. 5 Til denne lyofiliserede Handing sattes 0,5 ml af en urinprøve og derpå 0,5 ml destilleret vand. Efter 10 minutter bestemtes enzymaktiviteten i restvæsken ved hjælp af en papirstrimmel imprægneret med urinstof-hydrogenperoxid og o-tolidin. 10 Såfremt urinprøven stammede fra en gravid kvinde (> 2 IU HCG/ml), fremkom der en blå farve indenfor 5 minutter, hvorimod der, når urinprøven stammede fra en ikke-gravid kvinde, ikke fremkom nogen farve indenfor den samme tid. 15 „ ^ Patentkrav *
1. Fremgangsmåde til bestemmelse af en komponent i reaktionen 2Q mellem et specifikt binder-protein og det tilsvarende bindelige stof under anvendelse af den kendte bindingsaffinitet af sådanne komponenter indbyrdes, idet man ved bestemmelsen anvender en kendt mængde af et kob'lingsprodukt af det bindelige stof med et enzym og eventuelt også en kendt mængde af det specifikke binderyprotein 25 (i det tilfælde, at det bindelige stof er den komponent, der skal bestemmes), kendetegnet ved, at man yderligere anvender uopløseliggiorte antistoffer over for det specifikke binder-protein, og at man efter reaktionen bestemmer enzymaktiviteten i den flydende eller den faste fase af 3Q reaktionsblandingen. 1
2 Fremgangsmåde ifølge krav 1, kendetegnet ved, at man tilsætter de uopløselige antistoffer over for det specifikke binder-protein til reaktionsblandingen som det sidste reagens. 35 2 Fremgangsmåde ifølge krav 2 til bestemmelse af det bindelige stof, kendetegnet ved, at man først til prøven sætter det specifikke binder-protein og derpå enzymconjugatet og til sidst de uopløselige antistoffer over for det specifikke binder-
DK639871A 1970-12-28 1971-12-28 Fremgangsmaade og analysepakke til bestemmelse af en komponent i reaktionen mellem et specifikt binder-protein og det tilsvarende bindelige stof ved enzym-immunoanalyse DK150690C (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL7018838 1970-12-28
NL707018838A NL154599B (nl) 1970-12-28 1970-12-28 Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.

Publications (2)

Publication Number Publication Date
DK150690B true DK150690B (da) 1987-05-25
DK150690C DK150690C (da) 1988-06-06

Family

ID=19811894

Family Applications (1)

Application Number Title Priority Date Filing Date
DK639871A DK150690C (da) 1970-12-28 1971-12-28 Fremgangsmaade og analysepakke til bestemmelse af en komponent i reaktionen mellem et specifikt binder-protein og det tilsvarende bindelige stof ved enzym-immunoanalyse

Country Status (20)

Country Link
US (1) US3839153A (da)
JP (3) JPS5834783B1 (da)
AT (1) AT320145B (da)
AU (1) AU467394B2 (da)
BE (1) BE777309A (da)
BR (1) BR7108553D0 (da)
CA (1) CA964560A (da)
CH (1) CH557030A (da)
DE (1) DE2164768B2 (da)
DK (1) DK150690C (da)
EG (1) EG11604A (da)
ES (1) ES398372A1 (da)
FI (1) FI54034C (da)
FR (1) FR2120835A5 (da)
GB (1) GB1348938A (da)
IL (1) IL38371A (da)
IT (1) IT965020B (da)
NL (1) NL154599B (da)
SE (1) SE398557B (da)
ZA (1) ZA718332B (da)

Families Citing this family (884)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE31006E (en) * 1968-09-24 1982-08-03 Akzona Incorporated Process for the demonstration and determination of reaction components having specific binding affinity for each other
NL171930C (nl) * 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3790447A (en) * 1972-07-05 1974-02-05 Abbott Lab Streptococci diagnostic method
US4239746A (en) * 1973-06-30 1980-12-16 Dezso Istvan Bartos Complement fixation test employing reactants in a disposable package
DE2333434C3 (de) * 1973-06-30 1978-04-06 Istvan D. Dr. 5024 Pulheim Bartos Verfahren zur Durchführung serologischer Untersuchungen nach dem Prinzip der Komplementbindungsreaktion und gebrauchsfertige Schnelltestpackung hierfür
US3935074A (en) * 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
GB1508132A (en) * 1974-05-20 1978-04-19 Technicon Instr Analysis of biological fluids
US4040907A (en) * 1974-06-20 1977-08-09 Syva Company Iodothyronine enzyme conjugates
US4001087A (en) * 1974-10-10 1977-01-04 The United States Of America Affinity labelling enzymes with esters of aromatic sulfonic acids
FR2288312A1 (fr) * 1974-10-14 1976-05-14 Pasteur Institut Procede de dosage immunoenzymatique de la progesterone
US4002532A (en) * 1974-10-21 1977-01-11 Weltman Joel K Enzyme conjugates
SE388694B (sv) * 1975-01-27 1976-10-11 Kabi Ab Sett att pavisa ett antigen exv i prov av kroppvetskor, med utnyttjande av till porost berarmaterial bundna eller adsorberande antikroppar
NL7501215A (nl) * 1975-02-01 1976-08-03 Akzo Nv Methode voor het aantonen en bepalen van een antigeen of antilichaam.
US4629688A (en) * 1975-04-28 1986-12-16 Miles Laboratories, Inc. Homogeneous specific binding assay method
US4230797A (en) * 1975-04-28 1980-10-28 Miles Laboratories, Inc. Heterogenous specific binding assay employing a coenzyme as label
USRE32696E (en) * 1975-09-04 1988-06-14 Akzona Incorporated Enzymatic immunological method for determination of antigens and antibodies
US4474878A (en) * 1975-09-29 1984-10-02 Cordis Laboratories, Inc. Sandwich EIA for antigen associated with hepatitis
US4642285A (en) * 1975-09-29 1987-02-10 Diamedix Corporation Sandwich EIA for antigen
SE7610683L (sv) * 1975-09-29 1977-06-10 Cordis Corp Metod for bestemning av nervaron av ett antigen associerat med hepatit
JPS5272284A (en) * 1975-12-12 1977-06-16 Dainippon Pharmaceutical Co Enzymeeimmunoassay reagent
US4045384A (en) * 1976-07-23 1977-08-30 The Dow Chemical Company Method for forming an amide bond between a latex and protein
GB1549069A (en) * 1976-12-10 1979-08-01 Erba Farmitalia Enzyme linked immunoassay
US4200690A (en) * 1976-12-16 1980-04-29 Millipore Corporation Immunoassay with membrane immobilized antibody
US4407943A (en) * 1976-12-16 1983-10-04 Millipore Corporation Immobilized antibody or antigen for immunoassay
JPS5399319A (en) * 1977-02-09 1978-08-30 Hidematsu Hirai Novel qualitative and quantitative detecting method and detecting body for antgenic substance
IT1114861B (it) * 1977-05-12 1986-01-27 Sclavo Inst Sieroterapeut Metodo per la determinazione del contenuto di costituenti di fluidi biologici e mezzi adatti allo scopo
AU531777B2 (en) * 1978-04-05 1983-09-08 Syva Co. Label/solid conjugate immunoassay system
US4233402A (en) * 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
US4492751A (en) * 1978-04-10 1985-01-08 Miles Laboratories, Inc. Heterogenous specific binding assay employing an enzyme substrate as label
US4318980A (en) * 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
FR2422956A1 (fr) * 1978-04-13 1979-11-09 Pasteur Institut Procede de detection et de caracterisation d'un acide nucleique ou d'une sequence de celui-ci, et reactif enzymatique pour la mise en oeuvre de ce procede
US5605800A (en) * 1978-04-13 1997-02-25 Institut Pasteur Method of detecting and characterizing a nucleic acid or a sequence of the latter, and enzymatic reactant for the application of this method
JPS5510590A (en) * 1978-05-04 1980-01-25 Wellcome Found Enzyme immunity quantity analysis
JPS5539702A (en) * 1978-08-30 1980-03-19 Takeda Chem Ind Ltd Method of measuring enzyme immunity of pancreas glucagon
FR2440555A1 (fr) * 1978-10-31 1980-05-30 Maes Roland Perfectionnements aux procedes de determination de substances montrant entre elles des affinites de liaison specifiques, par des tests faisant intervenir une phase solide
US4260678A (en) * 1979-02-23 1981-04-07 Corning Glass Works Determining creatine kinase isoenzmes via immobilized antibody-isoenzyme complexes
JPS55152459A (en) * 1979-05-18 1980-11-27 Yamasa Shoyu Co Ltd Method and reagent for measuring quantity of cyclic nucleotide
US4289748A (en) * 1979-05-31 1981-09-15 United States Of America Ultrasensitive enzymatic radioimmunoassay method
DE2930706A1 (de) * 1979-07-28 1981-02-05 Medac Klinische Spezialpraep Verfahren zum nachweis von erregerspezifischen antikoerpern
US4299916A (en) * 1979-12-26 1981-11-10 Syva Company Preferential signal production on a surface in immunoassays
US4394391A (en) * 1980-02-19 1983-07-19 Thorell Jan Ivan Radioimmunoassay reagents
US4322495A (en) * 1980-03-11 1982-03-30 Minnesota Mining And Manufacturing Co. Immunoassay
EP0040728A1 (en) * 1980-05-19 1981-12-02 Pharmacia Diagnostics Ab An improvement in and relating to assaying methods involving biospecific affinity reactions
SE8003732L (sv) * 1980-05-19 1981-11-20 Pharmacia Diagnostics Ab Sett vid bestemningsmetoder involverande biospecifika affinitetsreaktioner
JPS5714748A (en) * 1980-07-01 1982-01-26 Dainippon Pharmaceut Co Ltd Kit for quantitative determination of valproic acid and its method for quantitative determination
US4323647A (en) * 1980-10-15 1982-04-06 University Of Miami Steric hindrance enzyme immunoassay
DE3048884A1 (de) * 1980-12-23 1982-07-15 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur enzymimmunobestimmung in heterogener phase
ES8307897A1 (es) * 1981-04-13 1983-08-01 Hoechst Co American Un metodo de determinar la presencia de un antigeno en un medio liquido sospechoso de contenerlo.
US4604365A (en) * 1981-06-02 1986-08-05 Electro-Nucleonics, Inc. Immunoprecipitation assay
WO1982004323A1 (en) * 1981-06-02 1982-12-09 O Neill Sean Immunoprecipitation assay
US4506009A (en) * 1982-03-30 1985-03-19 University Of California Heterogeneous immunoassay method
US4535057A (en) * 1982-07-26 1985-08-13 Amf Incorporated Immunoassay employing monoclonal herpes simplex antibody and biotin-avidin detection system
US4515890A (en) * 1982-11-08 1985-05-07 Abbott Laboratories Immunoassay of terminal deoxynucleotidyl transferase
US4650751A (en) * 1983-04-29 1987-03-17 Technicon Instruments Corporation Protected binding assay avoiding non-specific protein interference
US4778752A (en) * 1983-10-11 1988-10-18 Scripps Clinic And Research Foundation Receptors specific for hapten-modified self proteins
US4937199A (en) * 1985-03-18 1990-06-26 The Royal Free Hospital School Of Medicine Detection of viruses and antibodies
JPS62148857A (ja) * 1985-12-24 1987-07-02 Toyo Soda Mfg Co Ltd 免疫測定用材料の製造方法
EP0247730A3 (en) * 1986-04-28 1989-04-12 Antibody Technology Limited Antibodies, their preparation and use and products containing them
DE3636724A1 (de) * 1986-10-29 1988-06-23 Joern Dr Med Kekow Enzymimmunoassay (elisa) zur insulinbestimmung im mikrotiterplattensystem
US6528292B1 (en) * 1987-05-29 2003-03-04 Aventis Pharmaceuticals Holdings Inc. Derivatized polystyrene and other polymer supports for spectroscopic studies
US5256372A (en) * 1987-11-06 1993-10-26 Idexx Corporation Dipstick test device including a removable filter assembly
US5137804A (en) * 1988-05-10 1992-08-11 E. I. Du Pont De Nemours And Company Assay device and immunoassay
US5374524A (en) * 1988-05-10 1994-12-20 E. I. Du Pont De Nemours And Company Solution sandwich hybridization, capture and detection of amplified nucleic acids
US5614504A (en) * 1990-08-01 1997-03-25 The University Of South Florida Method of making inosine monophosphate derivatives and immunopotentiating uses thereof
CA2113823A1 (en) * 1991-07-19 1993-02-04 Cytimmune Sciences, Inc. Method and kit for measuring endogenous cytokines
US5965379A (en) * 1991-07-19 1999-10-12 Cytimmune Sciences Inc. Method for measuring endogenous cytokines
US5464749A (en) 1991-07-22 1995-11-07 Bayer Corporation Immunoassay of free substances in biological fluids
US5874423A (en) * 1992-09-10 1999-02-23 Yissum Research Development Co. Of The Hebrew University Of Jerusalem Digitalis-like compounds
US5637467A (en) * 1992-10-13 1997-06-10 Behringwerke Ag Heterogeneous assay using a pendulous drop
AU2635295A (en) * 1994-06-13 1996-01-05 Henry Ford Health System A novel neuronal-neonatal gene: neuronatin
US5843673A (en) * 1994-10-25 1998-12-01 Curators Of The University Of Missouri Method of screening for endometriosis
US6531277B2 (en) 1994-10-25 2003-03-11 The Curators Of The University Of Missouri Endometriosis-specific secretory protein
US20030152909A1 (en) * 1994-11-16 2003-08-14 Mitrani Eduardo N. In vitro micro-organs, and uses related thereto
US5607565A (en) * 1995-03-27 1997-03-04 Coulter Corporation Apparatus for measuring analytes in a fluid sample
US5777093A (en) * 1995-05-16 1998-07-07 Ramot-University Authority For Applied Research & Industrial Development Ltd. cDNAs associated with ataxia-telangiectasia
US5728807A (en) * 1995-05-16 1998-03-17 Ramot-University Authority For Applied Research And Industrial Development, Ltd. Mutated proteins associated with ataxia-telangiectasia
US5858661A (en) 1995-05-16 1999-01-12 Ramot-University Authority For Applied Research And Industrial Development Ataxia-telangiectasia gene and its genomic organization
US6096508A (en) * 1995-08-16 2000-08-01 Kirkegaard & Perry Laboratoies, Inc. Method of reducing background in biotin-based assays
US5840322A (en) * 1996-12-19 1998-11-24 Ramot-University Authority For Applied Research & Industrial Devel. Ltd. Anti-oral-microbial adhesion fraction derived from vaccinium
DE69829857T2 (de) * 1997-08-21 2006-02-02 Quark Biotech, Inc., Pleasanton Hypoxie-regulierte gene
US7973156B2 (en) 1997-08-21 2011-07-05 Quark Pharmaceuticals Inc. Hypoxia-regulated genes
US6284496B1 (en) 1997-10-03 2001-09-04 University Of South Florida DNA vector for determining the presence of out-of-reading-frame mutations
AU748467B2 (en) 1997-10-17 2002-06-06 University Of South Florida Method to diagnose and monitor cellular immune deficiencies
US7687057B2 (en) 1998-01-09 2010-03-30 Yissum Research Development Company Of The Hebrew University Of Jerusalem In vitro micro-organs, and uses related thereto
US20080206206A1 (en) 1998-05-07 2008-08-28 University Of South Florida Bone marrow-derived neuronal cells
US6344443B1 (en) 1998-07-08 2002-02-05 University Of South Florida Peptide antagonists of tumor necrosis factor alpha
US7605149B1 (en) 1998-07-13 2009-10-20 University Of South Florida Modulation of the phospholipase A2 pathway as a therapeutic
US6187563B1 (en) 1998-08-07 2001-02-13 Yale University βIV-spectrin-polypeptides and nucleic acids encoding same
JP2003523166A (ja) 1998-09-29 2003-08-05 ガミダ セル リミテッド 幹細胞および前駆細胞の増殖と分化を制御する方法
BR0009403A (pt) 1999-02-04 2001-11-27 Technion Res & Dev Foundation Método de expansão/conservação das células detronco hemopoiéticas indiferenciadas ou dascélulas progenitoras, método de preparação deum meio condicionado de célula estomacal útil naexpansão/conservação das células de troncohemopoiéticas indiferenciadas ou das célulasprogenitoras, método de transplante de célulasde tronco hemopoiéticas indiferenciadas ou decélulas progenitoras em um recipiente, tampão debiorreator e biorreator
US6440682B1 (en) * 1999-05-28 2002-08-27 Detroit R&D Inc. Detection of hypertension using immunoreactive metabolic products
US6787318B1 (en) * 1999-06-01 2004-09-07 Roskamp Research Institute, Llc Assay for evaluating the therapeutic effectiveness of agents in reducing Alzheimer's disease pathology
US7534605B2 (en) 1999-06-08 2009-05-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
CA2377541A1 (en) * 1999-06-25 2001-01-04 Eduardo N. Mitrani Method of inducing angiogenesis by micro-organs
US6875582B1 (en) 1999-08-19 2005-04-05 Omniscience Pharmaceuticals, Inc. Methods and targets of antibiotic resistance
US7101839B1 (en) 1999-08-30 2006-09-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods of and compositions for inhibiting the proliferation of mammalian cells
US7811981B2 (en) 1999-08-30 2010-10-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods of and compositions for inhibiting the proliferation of mammalian cells
US6998232B1 (en) 1999-09-27 2006-02-14 Quark Biotech, Inc. Methods of diagnosing bladder cancer
US7223902B1 (en) * 1999-11-19 2007-05-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of producing recombinant Aspergillus niger β-glucosidase and an aroma spreading plant
US6544506B2 (en) 2000-01-05 2003-04-08 Yeda Research & Development Co. Ltd. Veto cells effective in preventing graft rejection and devoid of graft versus host potential
WO2001053323A2 (en) * 2000-01-24 2001-07-26 Ramot University Authority For Applied Research & Industrial Development Ltd. Plants tolerant of environmental stress conditions, methods of generating same and novel polynucleotide sequence utilized thereby
DE60142475D1 (de) 2000-03-27 2010-08-12 Technion Res And Dev Of Founda Einkettige haupthistokompatibilitätskomplexe der klasse i (mhc-i), kodierende konstrukte und methoden ihrer erzeugung
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
IL135884A (en) * 2000-04-30 2005-08-31 Yissum Res Dev Co Method for measuring non-transferrin bound iron
HUP0300810A2 (hu) 2000-07-20 2003-08-28 M.G.V.S. Ltd. Mesterséges értranszplantátum, valamint ennek létrehozása és alkalmazása
US20040037828A1 (en) 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
US20030114410A1 (en) 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
DK2359854T3 (da) 2000-08-08 2013-11-04 Technion Res & Dev Foundation Farmaceutiske sammensætninger og fremgangsmåder egnet til modulering af angiogenese
EP1683874A3 (en) 2000-08-29 2006-10-11 YEDA RESEARCH AND DEVELOPMENT Co. LTD. Methods of isolating genes encoding proteins of specific function and of screening for pharmaceutically active agents
US7632522B2 (en) * 2000-09-28 2009-12-15 Nanocyte Inc. Use of stinging cells/capsules for the delivery of active agents to keratinous substances
US20070281037A9 (en) * 2000-09-28 2007-12-06 Nanocyte Inc. Sterile preparations and compositions including stinging capsules and methods of producing and using same
AU2001295850A1 (en) * 2000-09-28 2002-04-08 Nanocyte Inc. Methods, compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue
ES2425321T3 (es) 2000-11-17 2013-10-14 Vascular Biogenics Ltd. Promotores que muestran especificidad por células endoteliales y métodos de utilización de los mismos
US8071740B2 (en) 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
AU1846102A (en) 2000-11-24 2002-06-03 Cardimmune Ltd Methods employing and compositions containing defined oxidized phospholipids forprevention and treatment of atherosclerosis
US20040106120A1 (en) 2000-11-30 2004-06-03 Rachid Tazi-Ahnini Diagnosis and treatment of disease
EP1337152A4 (en) * 2000-11-30 2004-08-11 Yeda Res & Dev METHODS OF USING CULTURED T CELLS THAT DO NOT INDUCE HOST Graft Reaction (GVHD) TO TREAT DISEASE
US20020142287A1 (en) * 2000-12-14 2002-10-03 Hirotaka Yamamoto High throughput assay to detect inhibitors of the map kinase pathway
US7087395B1 (en) 2001-01-16 2006-08-08 Quest Diagnostics Investments Incorporated Vitamin D assay
WO2002057408A2 (en) * 2001-01-17 2002-07-25 Ramot At Tel Aviv University Ltd. Chitinases, derived from carnivorous plants polynucleotide sequences encoding thereof, and methods of isolating and using same
US20050202098A1 (en) 2001-01-31 2005-09-15 Tolaren Disease therapy using dying or dead cells
AU2002230061A1 (en) * 2001-01-31 2002-08-12 Tolaren Induction of tolerance by apoptotic and/or necrotic cells
US20030003454A1 (en) 2001-03-23 2003-01-02 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Methods and kits for determining a risk to develop cancer, for evaluating an effectiveness and dosage of cancer therapy and for correlating between an activity of a DNA repair enzyme and a cancer
US6770622B2 (en) 2001-06-08 2004-08-03 Gary A. Jarvis N-terminally truncated galectin-3 for use in treating cancer
WO2003008534A2 (en) * 2001-07-19 2003-01-30 Yissum Research Development Company Of The Hebrew University Of Jerusalem Polypeptides having carotenoids isomerase catalytic activity, nucleic acids encoding same and uses thereof
CA2458640A1 (en) 2001-08-16 2003-03-06 Bar-Ilan University Diagnosis, prevention and treatment of cancer
US7138144B2 (en) * 2001-09-07 2006-11-21 Nadir Askenasy Method of inducing immune tolerance via blood/lymph flow-restricted bone marrow transplantation
US20040136972A1 (en) 2001-09-07 2004-07-15 Yeda Research And Development Co. Ltd. Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues
US20060068405A1 (en) * 2004-01-27 2006-03-30 Alex Diber Methods and systems for annotating biomolecular sequences
CA2463816C (en) 2001-10-19 2014-07-08 Vascular Biogenics Ltd. Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy
AUPR842501A0 (en) * 2001-10-23 2001-11-15 Epipop Pty Ltd A method for identification and development of therapeutic agents
AU2002358947A1 (en) * 2001-12-05 2003-06-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Nanoparticles containing polymeric nucleic acid homologs, pharmaceutical compositions and articles of manufacture containing same and methods of use thereof
US20050085432A1 (en) * 2001-12-26 2005-04-21 Aviva Lapidot Methods of using conjugates of saccharides and acetamidino or guanidino compounds for treating bacterial infections
IL152904A0 (en) 2002-01-24 2003-06-24 Gamida Cell Ltd Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
EP1465982A4 (en) 2002-01-25 2006-06-07 Gamida Cell Ltd PROCESS FOR EXPANSION OF STEM AND PRESERVATIVE CELLS AND EXPANDED CELL POPULATIONS THEREWITH OBTAINED
US7781396B2 (en) * 2002-01-31 2010-08-24 Tel Aviv University Future Technology Development L.P. Peptides directed for diagnosis and treatment of amyloid-associated disease
US20040052928A1 (en) * 2002-09-06 2004-03-18 Ehud Gazit Peptides and methods using same for diagnosing and treating amyloid-associated diseases
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
AU2003216341A1 (en) * 2002-02-20 2003-09-09 Dyax Corporation Mhc-peptide complex binding ligands
WO2003078567A2 (en) * 2002-03-18 2003-09-25 Gamida-Cell Ltd. Methods of inducing differentiation in ex vivo expanded stem cells
ATE394125T1 (de) * 2002-03-26 2008-05-15 Nanocyte Inc Nesselzellen mit expression eines exogenen polynucleotids, das ein therapeutisches, diagnostisches oder kosmetisches mittel kodiert, und diese nesselzellen verwendende verfahren, zusammensetzungen und vorrichtungen oder daraus gewonnene kapseln zur abgabe des therapeutischen, diagnostischen oder kosmetischen mittels in ein gewebe
US20040121442A1 (en) * 2002-05-05 2004-06-24 Ilan Chet Fungal chitinase, polynucleotide sequences encoding same, promoters of same, and uses thereof
AU2003242967A1 (en) * 2002-07-12 2004-02-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method and device for inducing biological processes by micro-organs
EP2561889A3 (en) 2002-08-01 2013-04-03 Yeda Research and Development Co. Ltd. Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels
US7267981B2 (en) 2002-10-07 2007-09-11 Technion Research & Development Foundation Ltd. Human foreskin fibroblasts for culturing ES cells
US20040146949A1 (en) * 2002-10-25 2004-07-29 Jun Tan Methods and compounds for disruption of CD40R/CD40L signaling in the treatment of alzheimer's disease
EP2295980A1 (en) 2002-10-30 2011-03-16 Yissum Research Development Company, of The Hebrew University of Jerusalem Molecules and methods using same for measuring non-transferrin bound iron
US20050054097A1 (en) * 2002-11-17 2005-03-10 Tony Peled EX-VIVO expansion of hematopoietic system cell populations in mononuclear cell cultures
WO2004050826A2 (en) * 2002-11-29 2004-06-17 Technion Research & Development Foundation Ltd. Method of dynamically culturing embryonic stem cells
US7491699B2 (en) * 2002-12-09 2009-02-17 Ramot At Tel Aviv University Ltd. Peptide nanostructures and methods of generating and using the same
WO2004052275A2 (en) 2002-12-12 2004-06-24 R.B.T. (Rakuto Bio Technologies) Ltd. Methods of producing lignin peroxidase and its use in skin and hair lightening
ES2705683T3 (es) 2002-12-16 2019-03-26 Technion Res & Dev Foundation Medio de cultivo de células madre pluripotentes
JP2006512079A (ja) 2003-01-02 2006-04-13 ラッパポート・ファミリー・インスティチュート・フォー・リサーチ・イン・ザ・メディカル・サイエンシズ 高血糖性患者の心疾患を予防するための抗酸化治療の有効性を予測する方法
ATE426575T1 (de) * 2003-01-07 2009-04-15 Univ Ramot Peptidenanostrukturen die fremdmaterial enthalten,und verfahren zur herstellung derselben
US7786071B2 (en) 2003-03-04 2010-08-31 Yeda Research And Development Co. Ltd. Pon polypeptides polynucleotides encoding same and compositions and methods utilizing same
US20050054103A1 (en) * 2003-03-07 2005-03-10 Tony Peled Expansion of renewable stem cell populations using modulators of PI 3-kinase
US8017113B2 (en) 2003-03-12 2011-09-13 Rappaport Family Institute For Research In The Medical Sciences Compositions and methods for diagnosing and treating an inflammation
US7294701B2 (en) * 2003-04-02 2007-11-13 Technion Research & Development Foundation Ltd. Antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same
ES2433440T3 (es) 2003-04-04 2013-12-11 Yeda Research And Development Co. Ltd. Anticuerpos contra MMP2 o MMP9 y composiciones farmacéuticas que contienen los mismos útiles para inhibir la actividad de dichas metaloproteínas
US8252588B2 (en) 2003-04-08 2012-08-28 Yeda Research And Development Co. Ltd. Stem cells having increased sensitivity to SDF-1 and methods of generating and using same
FR2853551B1 (fr) 2003-04-09 2006-08-04 Lab Francais Du Fractionnement Formulation stabilisante pour compositions d'immunoglobulines g sous forme liquide et sous forme lyophilisee
US7321065B2 (en) * 2003-04-18 2008-01-22 The Regents Of The University Of California Thyronamine derivatives and analogs and methods of use thereof
AU2005234725B2 (en) 2003-05-22 2012-02-23 Evogene Ltd. Methods of Increasing Abiotic Stress Tolerance and/or Biomass in Plants and Plants Generated Thereby
CA2978152C (en) 2003-05-22 2021-01-26 Evogene Ltd. Methods of increasing abiotic stress tolerance and/or biomass in plants and plants generated thereby
US7554007B2 (en) 2003-05-22 2009-06-30 Evogene Ltd. Methods of increasing abiotic stress tolerance and/or biomass in plants
US20050020499A1 (en) * 2003-05-27 2005-01-27 Bar Ilan University Methods of attenuating cocaine seeking behavior employing glial cell-derived neurotrophic factor (GDNF) and pharmaceutical compositions and articles of manufacture suited for use in practice of the method
US8129514B2 (en) * 2003-06-19 2012-03-06 Evogene Ltd. Nucleotide sequences for regulating gene expression in plant trichomes and constructs and methods utilizing same
US7498428B2 (en) * 2003-06-19 2009-03-03 Evogene Ltd. Nucleotide sequences for regulating gene expression in plant trichomes and constructs and methods utilizing same
JP5137400B2 (ja) 2003-06-30 2013-02-06 テル アヴィヴ ユニヴァーシティ フューチャー テクノロジー ディヴェロップメント エル.ピー. アミロイド関連疾患を診断および処置するためのペプチド、それに対する抗体、ならびにその使用方法
CN101076585A (zh) * 2003-08-14 2007-11-21 生物平衡公司 细菌株系、包括该细菌株系的组合物和其益生菌用途
WO2005031362A2 (en) 2003-10-02 2005-04-07 Ramot At Tel Aviv University Ltd. Novel antibacterial agents and methods of identifying and utilizing same
IL158287A0 (en) 2003-10-07 2004-05-12 Yeda Res & Dev Antibodies to nik, their preparation and use
DK1678209T3 (da) 2003-10-07 2011-06-27 Yeda Res & Dev Antistoffer mod nik, deres frembringelse samt anvendelse
EP1678294A1 (en) * 2003-10-23 2006-07-12 Pfizer Products Inc. Vaccine for periodontal disease
JP5039383B2 (ja) 2003-11-30 2012-10-03 イエダ リサーチ アンド ディベロップメント カンパニー リミテッド 免疫モジュレーションのための方法および薬剤ならびに免疫モジュレーターの同定方法
WO2005059100A2 (en) * 2003-12-12 2005-06-30 New York University Methods and compositions relating to cystatin c
US20100221233A1 (en) * 2003-12-15 2010-09-02 University Of South Florida Compositions and methods for enhancing neuroprotection via administration of stem cells and blood brain barrier permeabilizers
EP2289567A3 (en) 2003-12-22 2011-06-22 Regentis Biomaterials Ltd. Matrix comprising naturally-occurring crosslinked protein backbone
US8007847B2 (en) 2004-01-13 2011-08-30 Eytan Biderman Feeding formula appliance
US7423139B2 (en) * 2004-01-20 2008-09-09 Insight Biopharmaceuticals Ltd. High level expression of recombinant human erythropoietin having a modified 5′-UTR
EP1729793B1 (en) 2004-03-02 2015-07-22 Acceleron Pharma Inc. Alk7 and myostatin inhibitors for muscle wasting disorders
US8352031B2 (en) 2004-03-10 2013-01-08 Impulse Dynamics Nv Protein activity modification
CA2570195C (en) 2004-06-14 2017-10-24 Evogene Ltd. Polynucleotides and polypeptides involved in plant fiber development and methods of using same
US8962915B2 (en) 2004-06-14 2015-02-24 Evogene Ltd. Isolated polypeptides, polynucleotides encoding same, transgenic plants expressing same and methods of using same
US8680062B2 (en) * 2004-07-06 2014-03-25 Deliversir Ltd. System for delivering therapeutic agents into living cells and cells nuclei
WO2006006172A2 (en) * 2004-07-15 2006-01-19 Ramot At Tel Aviv University Ltd. Use of anti-amyloid agents for treating and typing pathogen infections
EP1799812A4 (en) 2004-09-16 2009-09-09 Gamida Cell Ltd EX VIVO CULTIVATION METHODS OF STEM CELLS AND PRECURSOR BY CO-CULTURE WITH MESENCHYMAL CELLS
US20060095241A1 (en) * 2004-10-29 2006-05-04 Microsoft Corporation Systems and methods that utilize machine learning algorithms to facilitate assembly of aids vaccine cocktails
US8000900B2 (en) 2004-09-21 2011-08-16 Microsoft Corporation Association-based predictions of pathogen characteristics
EP1805319B1 (en) * 2004-09-29 2014-09-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Recombinant human t2 rnase and uses thereof
DE602005023332D1 (de) 2004-09-29 2010-10-14 Collplant Ltd Kollagenproduzierende pflanzen sowie verfahren zu deren erzeugung und verwendung
EP1809374A4 (en) * 2004-10-12 2008-09-10 Closed Loop Therapies Ltd IMPLANTABLE METHODS AND DEVICES FOR TREATING SUPRAVENTRICULAR ARRHYTHMIAS
US8478535B2 (en) 2004-10-29 2013-07-02 Microsoft Corporation Systems and methods that utilize machine learning algorithms to facilitate assembly of aids vaccine cocktails
US20060134680A1 (en) * 2004-12-22 2006-06-22 Alexander Kotlyar Homogeneous populations of nucleic acids, methods of synthesyzing same and uses thereof
US20080082678A1 (en) * 2005-01-16 2008-04-03 Zlango Ltd. Communications Network System and Methods for Using Same
JP2008527563A (ja) 2005-01-16 2008-07-24 ズランゴー リミテッド アイコニック通信
WO2007080558A2 (en) * 2006-01-16 2007-07-19 Zlango Ltd. Communications network system and methods for using same
DK1843850T3 (da) 2005-01-31 2015-12-07 Realbio Technologies Ltd Kapillaranordning med lateral strømning til flertrinsreaktion
EP2316441A1 (en) 2005-02-17 2011-05-04 Hadasit Medical Research Services And Development Bisphosphonates for treating endometriosis
JP5432455B2 (ja) 2005-02-25 2014-03-05 ザ ステート オブ イスラエル、ミニストリー オブ アグリカルチャー アンド ルーラル ディベロップメント、アグリカルチュラル リサーチ オーガナイゼイション、(エー.アール.オー.)、ボルカニ センター 炎症治療用の果実細胞培養抽出物
US7695927B2 (en) * 2005-03-18 2010-04-13 Detroit R & D Detection of hypertension using glucuronidated metabolic products
WO2006109312A2 (en) * 2005-04-15 2006-10-19 Vascular Biogenics Ltd. Compositions containing beta 2-glycoprotein i-derived peptides for the prevention and/or treatment of vascular disease
US8834862B2 (en) * 2005-04-19 2014-09-16 Nanocyte Inc. Methods, compositions and devices utilizing stinging cells/capsules for conditioning a tissue prior to delivery of an active agent
CA2606018A1 (en) * 2005-04-28 2006-11-02 Ventana Medical Systems, Inc. Nanoparticle conjugates
US20060246523A1 (en) 2005-04-28 2006-11-02 Christopher Bieniarz Antibody conjugates
EP1888034A2 (en) 2005-05-26 2008-02-20 Yissum Research Development Company, of The Hebrew University of Jerusalem Compositions and methods using same for delivering agents into a target organ protected by a blood barrier
EP1893747B1 (en) 2005-06-16 2014-09-03 Ramot at Tel Aviv University Ltd. Isolated cells and populations comprising same for the treatment of cns diseases
US20070225242A1 (en) * 2005-06-21 2007-09-27 The Board Of Trustees Of The Leland Stanford Junior University Method and composition for treating and preventing tumor metastasis in vivo
WO2007007317A1 (en) 2005-07-07 2007-01-18 Yissum Research Development Company Of The Hebrew University Of Jerusalem Nucleic acid agents for downregulating h19, and methods of using same
WO2007007325A2 (en) 2005-07-07 2007-01-18 Fulcrum Sp Ltd. Sp1 polypeptides, modified sp1 polypeptides and uses thereof
BRPI0616012A2 (pt) 2005-07-18 2011-05-31 Protalix Ltd administração via mucosa ou intestino de macromoléculas biologicamente ativas
EP2889041A1 (en) 2005-07-26 2015-07-01 Rutgers, The State University of New Jersey Kit of reagents for tuberculosis assay
CA2615460A1 (en) * 2005-08-08 2007-02-15 Onconon, Llc Antibody compositions, methods for treating neoplastic disease and methods for regulating fertility
EP1928479B1 (en) 2005-08-24 2016-06-08 Yeda Research And Development Co., Ltd. Universal donor-derived tolerogenic cells for inducing non-syngeneic transplantation tolerance
WO2007026353A2 (en) 2005-08-29 2007-03-08 Technion Research & Development Foundation Ltd. Media for culturing stem cells
WO2007034487A1 (en) 2005-09-22 2007-03-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Nucleic acid constructs, pharmaceutical compositions and methods of using same for treating cancer
US20070087437A1 (en) * 2005-10-14 2007-04-19 Jifan Hu Methods for rejuvenating cells in vitro and in vivo
WO2007057967A1 (ja) * 2005-11-18 2007-05-24 Mitsubishi Denki Kabushiki Kaisha エレベータのかご照明装置
DK2963011T3 (da) * 2005-11-23 2018-08-06 Ventana Med Syst Inc Molekylært konjugat
US8846393B2 (en) 2005-11-29 2014-09-30 Gamida-Cell Ltd. Methods of improving stem cell homing and engraftment
JP5102773B2 (ja) 2005-11-29 2012-12-19 ガミダ セル リミテッド 幹細胞のホーミングおよび生着を改善する方法
US20070134739A1 (en) * 2005-12-12 2007-06-14 Gyros Patent Ab Microfluidic assays and microfluidic devices
EP2237037A1 (en) 2005-12-12 2010-10-06 Gyros Patent Ab Microfluidic device and use thereof
US8775526B2 (en) 2006-01-16 2014-07-08 Zlango Ltd. Iconic communication
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US8759292B2 (en) 2006-02-03 2014-06-24 Prolor Biotech, Llc Long-acting coagulation factors and methods of producing same
US8476234B2 (en) 2006-02-03 2013-07-02 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US8048848B2 (en) 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US7553941B2 (en) 2006-02-03 2009-06-30 Modigene Inc Long-acting polypeptides and methods of producing same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
CN101416063A (zh) 2006-02-06 2009-04-22 拉帕波特家族医学科学研究所 用于诊断t1dm的方法和试剂盒
CA2641954C (en) 2006-03-06 2016-04-26 Zetiq Technologies Ltd. Methods and compositions for identifying a cell phenotype
EP2548951B1 (en) 2006-03-23 2016-05-04 Pluristem Ltd. Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
EP2004858A4 (en) 2006-03-28 2009-12-09 Tel Hashomer Medical Res Infrastructure & Services Ltd METHOD AND KITS FOR DETERMINING AN INVESTMENT TO WARFARINE RESISTANCE
KR20090029184A (ko) * 2006-04-07 2009-03-20 더 가브먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 항체 조성물 및 신생물성 질병의 치료 방법
US7977457B2 (en) * 2006-05-19 2011-07-12 Teva Pharmaceutical Industries Ltd. Fusion proteins, uses thereof and processes for producing same
US20070281883A1 (en) * 2006-06-05 2007-12-06 Hanna Rosenfeld Development of follicle stimulating hormone agonists and antagonists in fish
EP2046109A4 (en) 2006-07-20 2010-01-06 Yeda Res & Dev PHOTOSYNTHETIC ORGANISMS, COMPOSITIONS AND METHODS FOR GENERATING THESE ORGANISMS
US8809052B2 (en) 2006-08-28 2014-08-19 Yeda Research And Development Co. Ltd. Methods of generating mature oligodendrocytes
CA2664972C (en) 2006-10-05 2016-07-26 Technion Research & Development Foundation Ltd. Microtubes and methods of producing same
US7888059B2 (en) * 2006-10-05 2011-02-15 Yeda Research And Development Co. Ltd. Highly purified and stabilized Na,K-ATPase isoforms and methods of producing same
EP2096909A4 (en) 2006-12-20 2010-08-04 Evogene Ltd POLYNUCLEOTIDES AND POLYPEPTIDES INVOLVED IN THE DEVELOPMENT OF VEGETABLE FIBERS AND METHODS OF USE
US20100086526A1 (en) * 2007-01-16 2010-04-08 Abraham Hochberg Nucleic acid constructs and methods for specific silencing of h19
WO2008093331A1 (en) * 2007-01-29 2008-08-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Antibody conjugates for circumventing multi-drug resistance
WO2008093341A2 (en) 2007-01-31 2008-08-07 Technion Research & Development Foundation Ltd. Electrospun scaffolds and methods of generating and using same
US8546333B2 (en) 2007-02-01 2013-10-01 Technion Research & Development Foundation Limited Albumin fibers and fabrics and methods of generating and using same
ES2662036T3 (es) 2007-02-28 2018-04-05 Yeda Research And Development Company Limited Secuencias que se dirigen al núcleo
CA2682093A1 (en) 2007-03-29 2008-10-09 Technion Research & Development Foundation Ltd. Antibodies, methods and kits for diagnosing and treating melanoma
JP2010523104A (ja) 2007-04-02 2010-07-15 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド ガン細胞検出方法ならびにガン疾患の診断およびガン疾患の処置のモニタリングのためのその使用
CN101854798B (zh) 2007-04-09 2013-04-03 伊沃基因有限公司 用于增加植物的油含量、生长速率和/或产量的多核苷酸、多肽和方法
US9556210B2 (en) 2007-04-23 2017-01-31 Sabag-Rfa Ltd. System for delivering therapeutic agents into living cells and cells nuclei
PT2144633E (pt) * 2007-04-23 2014-10-27 Deliversir Ltd Um sistema para a administração de agentes terapêuticos em células vivas e núcleos de células
US9156865B2 (en) 2007-04-23 2015-10-13 Deliversir Ltd System for delivering therapeutic agents into living cells and cells nuclei
US8338113B2 (en) 2007-05-01 2012-12-25 Tel Hashomer Medical Research Infrastructure And Services Ltd. Methods for detecting fetal cells in the maternal blood
JP2010530735A (ja) 2007-05-03 2010-09-16 エージェンシー フォー サイエンス,テクノロジー アンド リサーチ 細胞内のprl−1ポリペプチドまたはprl−3ポリペプチドに結合する抗体
CN101861382B (zh) 2007-05-07 2015-07-15 普罗塔里克斯有限公司 大规模一次性生物反应器
US20100197767A1 (en) 2007-07-11 2010-08-05 Lior Nissim Nucleic acid construct systems capable of daignosing or treating a cell state
JP2010533705A (ja) 2007-07-15 2010-10-28 ヒルマン,イチャク 抗菌ペプチドまたはその阻害剤を用いた疾病治療
IL184627A0 (en) 2007-07-15 2008-12-29 Technion Res & Dev Foundation Agents for diagnosing and modulating metastasis and fibrosis as well as inflammation in a mammalian tissue
AU2008278654B2 (en) 2007-07-24 2014-06-05 Evogene Ltd. Polynucleotides, polypeptides encoded thereby, and methods of using same for increasing abiotic stress tolerance and/or biomass and/or yield in plants expressing same
CA2693310C (en) * 2007-08-02 2018-11-27 Arresto Biosciences, Inc. Lox and loxl2 inhibitors, antibodies and uses thereof
DK2185175T3 (da) 2007-08-15 2013-05-13 Yeda Res & Dev MMP-9-regulatorer og anvendelser deraf
AU2008299318A1 (en) 2007-09-12 2009-03-19 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Methods of treating tumors in immune-privileged sites
KR20140107677A (ko) 2007-09-19 2014-09-04 플루리스템 리미티드 지방 또는 태반 조직 유래의 부착 세포 및 이의 치료 용도
EP2210092B1 (en) 2007-10-19 2014-06-11 Rappaport Family Institute for Research in the Medical Sciences Compositions comprising semaphorins for the treatment of angiogenesis related diseases and methods of selection thereof
JP2011504374A (ja) 2007-11-26 2011-02-10 イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム リミテッド 繊維状ポリペプチドおよび多糖を含む組成物
EP2240510B1 (en) 2007-12-27 2017-05-10 Evogene Ltd. Isolated polypeptides, polynucleotides useful for modifying salinity stress tolerance in plants
EP2245055A2 (en) * 2008-01-31 2010-11-03 Compugen Ltd. Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
EP2265751B1 (en) 2008-02-21 2015-04-01 Technion Research & Development Foundation Ltd. Method for depleting or isolating a molecule from a solution
US8747855B2 (en) * 2008-04-09 2014-06-10 Technion Research & Development Foundation Limited Anti human immunodeficiency antibodies and uses thereof
EP2297200A1 (en) * 2008-04-09 2011-03-23 Technion Research & Development Foundation Ltd. Anti influenza antibodies and uses thereof
EP2508325A3 (en) * 2008-04-10 2013-05-22 Objet Ltd. System and method for three dimensional model printing
US9095569B2 (en) 2008-04-18 2015-08-04 Collplant Ltd. Methods of generating and using procollagen
US8791324B2 (en) 2008-04-21 2014-07-29 Danziger Innovations Ltd. Plant viral expression vectors and use of same for generating genotypic variations in plant genomes
JP2010043063A (ja) 2008-05-09 2010-02-25 Agency For Science Technology & Research 川崎病の診断及び治療
CA3148194A1 (en) 2008-05-22 2009-11-26 Evogene Ltd. Isolated polynucleotides and peptides and methods of using same for increasing plant yield, biomass, growth rate, vigor, oil content, abiotic stress tolerance of plants and nitrogen use efficiency
EP2641606A1 (en) 2008-05-27 2013-09-25 Pluristem Ltd. Methods of treating inflammatory colon diseases
EP2620493B1 (en) 2008-05-28 2019-03-27 Ramot at Tel Aviv University Ltd. Mesenchymal stem cells for the treatment of CNS diseases
WO2010007613A1 (en) 2008-06-29 2010-01-21 Realbio Technologies Ltd. Liquid–transfer device particularly useful as a capturing device in a biological assay process
JP5583667B2 (ja) 2008-08-08 2014-09-03 ジェニスフィア・エルエルシー 長時間作用型dnaデンドリマーおよびその方法
JP5756014B2 (ja) 2008-08-08 2015-07-29 エイジェンシー・フォー・サイエンス,テクノロジー・アンド・リサーチ(エイ・スター) がんの診断および治療のためのvhz
WO2010020941A2 (en) 2008-08-18 2010-02-25 Evogene Ltd. Isolated polypeptides and polynucleotides useful for increasing nitrogen use efficiency, abiotic stress tolerance, yield and biomass in plants
RU2539786C2 (ru) 2008-09-02 2015-01-27 Плуристем Лтд. Выращенные в прикрепленной к субстрату культуре клетки из ткани плаценты и их использование при лечении
US8367392B2 (en) * 2008-09-05 2013-02-05 Transalgae Ltd. Genetic transformation of algal and cyanobacteria cells by microporation
US20110305682A1 (en) 2008-09-11 2011-12-15 Ben Gurion University Of The Negev Research And Development Authority Compositions and Methods for Treating S. Pneumonia Infection
BRPI0919020B8 (pt) 2008-09-12 2021-05-25 Cryopraxis Criobiologia Ltda uso de células de linhagem monocitária enriquecidas para tratar isquemia e para tratar angina pectoris
KR101594202B1 (ko) 2008-09-24 2016-02-15 텔 하쇼머 메디컬 리서치 인프라스트럭쳐 앤드 서비시스 리미티드. 세포 유착 방지를 위한 펩티드와 조성물 및 그것의 사용 방법
EP2342356A4 (en) 2008-09-29 2012-11-21 Univ Ben Gurion AMYLOID BETA PEPTIDASES AND METHOD OF USE THEREOF
MX2011003575A (es) 2008-10-30 2011-04-21 Evogene Ltd Polinucleotidos y polipeptidos aislados y metodos para utilizarlos para aumentar el rendimiento de la planta, biomasa, tasa de crecimiento, vigor, contenido de aceite, tolerancia al estres abiotico de las plantas y eficacia en el uso de nitrogeno.
WO2010055525A1 (en) 2008-11-17 2010-05-20 Technion Research & Development Foundation Ltd. Method for predicting a patient's responsiveness to anti-folate therapy
WO2010058396A1 (en) 2008-11-19 2010-05-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. A cd44vra antibody and diagnostic and therapeutic methods using same
WO2010061383A1 (en) 2008-11-26 2010-06-03 Biodalia Microbiological Technologies Ltd. A method of in-situ enrichment of foods with fructan
WO2010064231A1 (en) 2008-12-02 2010-06-10 Tel Hashomer Medical Research Infrastructure And Services Ltd. Methods of analyzing a-i rna editing and nucleic acid constructs capable of same
WO2010064247A1 (en) 2008-12-03 2010-06-10 Tel Hashomer Medical Research Infrastructure And Services Ltd. Methods and kits for determining predisposition to cancer
US8734759B2 (en) 2008-12-05 2014-05-27 Yeda Research And Development Co. Ltd. Methods of diagnosing and treating motor neuron diseases
WO2010071610A1 (en) 2008-12-19 2010-06-24 Agency For Science, Technology And Research (A*Star) Severe chikungunya biomarkers
EP2376528B1 (en) 2008-12-29 2014-11-26 Tel Hashomer Medical Research, Infrastructure And Services Ltd. Peptides and compositions for prevention of cell adhesion and methods of using same
EP2373792B1 (en) 2008-12-29 2016-11-02 Evogene Ltd. Polynucleotides, polypeptides encoded thereby, and methods of using same for increasing abiotic stress tolerance, biomass and/or yield in plants expressing same
WO2010076788A2 (en) 2008-12-29 2010-07-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods of predicting responsiveness to interferon treatment and treating hepatitis c infection
WO2010076794A1 (en) 2008-12-31 2010-07-08 Technion Research & Development Foundation Ltd. Method of denitrifying brine and systems capable of same
WO2010080769A2 (en) 2009-01-06 2010-07-15 Arresto Biosciences, Inc. Chemotherapeutic methods and compositions
IL196820A0 (en) 2009-02-01 2009-11-18 Yissum Res Dev Co Devitalized, acellular scaffold matrices derived from micro-organs seeded with various cells
US8691760B2 (en) 2009-02-02 2014-04-08 Ramot At Tel-Aviv University Peptides, pharmaceutical compositions comprising same and uses thereof
WO2010089707A1 (en) 2009-02-04 2010-08-12 Yeda Research And Development Co. Ltd. Methods and kits for determining sensitivity or resistance of prostate cancer to radiation therapy
EP2401363B1 (en) 2009-02-26 2018-08-22 Tel HaShomer Medical Research Infrastructure and Services Ltd. Methods of reprogramming renal cells
LT3460062T (lt) 2009-03-02 2021-06-25 Evogene Ltd. Izoliuoti polinukleotidai ir polipeptidai, ir jų naudojimo būdai, skirti augalų derlingumui didinti ir (arba) žemės ūkio savybėms gerinti
US8546330B2 (en) 2009-03-09 2013-10-01 Ramot At Tel-Aviv University Ltd. Compositions and methods for treatment of neurodegenerative diseases
WO2010103517A1 (en) 2009-03-12 2010-09-16 Rappaport Family Institute For Research In The Medical Sciences Soluble compositions for the treatment of cxcr3-ligand associated diseases
WO2010113096A1 (en) 2009-03-30 2010-10-07 Tel Hashomer Medical Research Infrastructure And Services Ltd. Methods of predicting clinical course and treating multiple sclerosis
US8912142B2 (en) 2009-04-01 2014-12-16 The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center Method of regulating proliferation and differentiation of keratinocyes
WO2010116375A1 (en) 2009-04-08 2010-10-14 Yeda Research And Development Co. Ltd. Isolated peptides for regulating apoptosis
DK2424896T3 (da) 2009-04-30 2015-12-14 Tel Hashomer Medical Res Infrastructure & Services Ltd Anti-CEACAM1-antistoffer og fremgangsmåder til anvendelse deraf
CN102576024B (zh) 2009-05-19 2016-10-26 泽蒂克科技有限公司 宫颈癌细胞和/或组织的鉴别染色的试剂盒和方法
EP2435072A2 (en) 2009-05-27 2012-04-04 Yeda Research and Development Co. Ltd. Proteasome inhibitors and uses thereof
US20120078163A1 (en) 2009-05-27 2012-03-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method of generating connective tissue
WO2010137013A1 (en) 2009-05-27 2010-12-02 Ramot At Tel Aviv University Ltd. Crystallized photosystem i units from the pea plant and their use in solid state devices
US20120070449A1 (en) 2009-05-28 2012-03-22 Yeda Research And Development Co. Ltd. Methods of treating inflammation
MX381662B (es) 2009-06-10 2025-03-13 Evogene Ltd Polinucleotidos y polipeptidos aislados, y metodos para utilizarlos para mejorar la eficacia en el uso de nitrogeno, rendimiento, tasa de crecimiento, vigor, biomasa, contenido de aceite y/o tolerancia al estres abiotico.
EP2446267A1 (en) 2009-06-24 2012-05-02 Health Corporation - Rambam Methods and kits for isolating placental derived microparticles and use of same for diagnosis of fetal disorders
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
US12203113B2 (en) 2009-07-09 2025-01-21 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
WO2011004379A1 (en) 2009-07-10 2011-01-13 Tel Hashomer Medical Research Infrastructure And Services Ltd. Compositions and methods for treating cancer
CA2768725A1 (en) 2009-07-21 2011-01-27 Tel Hashomer Medical Research Infrastructure And Services Ltd. A method of diagnosing cancer
GB0913442D0 (en) 2009-07-31 2009-09-16 Univ Ramot Cell-targeting nanoparticles comprising polynucleotide agents and uses thereof
WO2011021194A2 (en) 2009-08-17 2011-02-24 Technion Research & Development Foundation Ltd. Pericyte progenitor cells and methods of generating and using same
EP2467396A4 (en) 2009-08-21 2012-12-26 Gilead Biologics Inc CATALYTIC DOMAINS FROM LYSYL OXIDASE AND LOXL2
US20120157512A1 (en) 2009-08-21 2012-06-21 Monsanto Technology Llc Preventing and Curing Beneficial Insect Diseases Via Plant Transcribed Molecules
WO2011022709A1 (en) * 2009-08-21 2011-02-24 Arresto Biosciences, Inc In vitro screening assays
WO2011024172A2 (en) 2009-08-27 2011-03-03 Technion Research & Development Foundation Ltd. Liposomal compositions and uses of same
EP2475784A1 (en) 2009-09-08 2012-07-18 Ramot at Tel-Aviv University Ltd. Methods of diagnosing amyotrophic lateral sclerosis (als)
WO2011030332A2 (en) 2009-09-08 2011-03-17 Yeda Research And Development Co. Ltd. Methods for hematopoietic precursor mobilization
US20120171213A1 (en) 2009-09-10 2012-07-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method of treating tumors
EP2478093A2 (en) 2009-09-17 2012-07-25 Yeda Research and Development Co. Ltd. Isolated pon1 polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage
JP2013505230A (ja) 2009-09-17 2013-02-14 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド 酸化ストレス関連障害を処置するためのペプチド
US8735124B2 (en) 2009-09-17 2014-05-27 Yeda Research And Development Co. Ltd. Isolated PON1 polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage
US20110081706A1 (en) * 2009-10-02 2011-04-07 TransAlgae Ltd Method and system for efficient harvesting of microalgae and cyanobacteria
US8962584B2 (en) 2009-10-14 2015-02-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Compositions for controlling Varroa mites in bees
MX353880B (es) 2009-10-14 2018-01-31 Yissum Research Development Company Of The Hebrew Univ Of Jerusalem Ltd Star Composiciones para controlar ácaros varroa en abejas.
ES2609006T3 (es) 2009-10-16 2017-04-18 Rutgers, The State University Of New Jersey Procedimeinto de tratamiento de lesión crónica de tejido nervioso usando una estrategia de terapia celular
WO2011048600A1 (en) 2009-10-21 2011-04-28 Danziger Innovations Ltd. Generating genotypic variations in plant genomes by gamete infection
IL201999A (en) 2009-11-08 2017-10-31 Medical Res & Development Fund For Health Services Bnai Zion Medical Center The State Of Israel A knockout mouse of the 1 – mo gene, a gene associated with morbidly extreme obesity
EP2498806B1 (en) 2009-11-12 2014-12-31 Ramot at Tel-Aviv University Ltd. Compositions comprising pedf and uses of same in the treatment and prevention of ovary-related syndromes
WO2011058555A1 (en) 2009-11-12 2011-05-19 Yeda Research And Development Co. Ltd. A method of editing dna in a cell and constructs capable of same
EP3633025B1 (en) 2009-11-12 2022-09-14 Technion Research & Development Foundation Ltd. Culture media, cell cultures and methods of culturing pluripotent stem cells in an undifferentiated state
WO2011061736A1 (en) 2009-11-17 2011-05-26 Protalix Ltd. Alkaline alpha galactosidase for the treatment of fabry disease
US20120273993A1 (en) 2009-11-24 2012-11-01 Collplant Ltd. Method of generating collagen fibers
CA2781649C (en) 2009-11-30 2017-07-11 Pluristem Ltd. Adherent cells from placenta and use of same in disease treatment
WO2011067745A2 (en) 2009-12-06 2011-06-09 Rosetta Green Ltd. Compositions and methods for enhancing plants resistance to abiotic stress
EP2510098B1 (en) 2009-12-09 2015-02-11 Quark Pharmaceuticals, Inc. Methods and compositions for treating diseases, disorders or injury of the cns
BR112012016033B1 (pt) 2009-12-28 2021-03-09 Evogene Ltd. métodos de aumento de produção de semente, biomassa, taxa de crescimento, vigor, tolerância à deficiência de nitrogênio, eficiência no uso de nitrogênio e/ou redução do tempo de florescimento de uma planta, e, para produzir uma planta transgênica
US20130011376A1 (en) 2009-12-29 2013-01-10 Gamida Cell Ltd. Methods for Enhancing Natural Killer Cell Proliferation and Activity
WO2011083464A2 (en) 2010-01-05 2011-07-14 Vascular Biogenics Ltd. Methods for use of a specific anti-angiogenic adenoviral agent
SG182490A1 (en) 2010-01-12 2012-08-30 Vascular Biogenics Ltd Methods of producing adenovirus vectors and viral preparations generated thereby
US8697078B2 (en) 2010-01-27 2014-04-15 Yeda Research And Development Co. Ltd. Antibodies that inhibit metalloproteins
US8680246B2 (en) 2010-02-04 2014-03-25 Gilead Biologics, Inc. Antibodies that bind to lysyl oxidase-like 2 (LOXL2)
WO2011099006A2 (en) 2010-02-11 2011-08-18 Yeda Research And Development Co. Ltd. Enzymatic systems for carbon fixation and methods of generating same
EP2538961B1 (en) 2010-02-24 2016-10-12 Ben Gurion University Of The Negev Research And Development Authority Inhibition of necrosis
WO2011107939A1 (en) 2010-03-01 2011-09-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods of predicting efficacy of an anti-vegfa treatment for solid tumors
WO2011107994A1 (en) 2010-03-04 2011-09-09 Yeda Research And Development Co. Ltd. Methods of measuring protein stability
WO2011111034A1 (en) 2010-03-08 2011-09-15 Yeda Research And Development Co. Ltd. Recombinant protein production in heterologous systems
ES2641642T3 (es) 2010-03-08 2017-11-10 Monsanto Technology Llc Moléculas de polinucleótido para regulación génica en plantas
CN102918159A (zh) 2010-03-11 2013-02-06 雅各布·埃德尔 产生氢的方法
EP2556085A2 (en) 2010-04-05 2013-02-13 Bar-Ilan University Protease-activatable pore-forming polypeptides
WO2011128897A1 (en) 2010-04-12 2011-10-20 Technion Research & Development Foundation Ltd. Populations of pancreatic progenitor cells and methods of isolating and using same
EP2557913B1 (en) 2010-04-12 2016-08-03 Ben Gurion University Of The Negev Research And Development Authority Sulfotransferase of a red microalga and uses thereof
EP2561356B1 (en) 2010-04-18 2016-08-03 Yeda Research and Development Co. Ltd. MOLECULES AND METHODS OF USING SAME FOR TREATING ErbB/ErbB LIGANDS ASSOCIATED DISEASES
US9328353B2 (en) 2010-04-28 2016-05-03 Evogene Ltd. Isolated polynucleotides and polypeptides for increasing plant yield and/or agricultural characteristics
US20130053277A1 (en) 2010-05-04 2013-02-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods of identifying inhibitors of polypeptides-of-interest
US9352000B2 (en) 2010-05-05 2016-05-31 Rappaport Family Institute For Research In The Medical Sciences Use of CCL1 in therapy
IL208820A0 (en) 2010-10-19 2011-01-31 Rachel Teitelbaum Biologic female contraceptives
EP2569417B1 (en) 2010-05-13 2018-04-18 Tel HaShomer Medical Research Infrastructure and Services Ltd. Isolated populations of adult renal cells and methods of isolating and using same
ES2410754T3 (es) 2010-05-25 2013-07-03 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Procedimiento para la detección electroquímica de reacciones de unión
EP2576806B1 (en) 2010-05-26 2017-03-08 The Board of Trustees of the University of Illionis Personal glucose meters for detection and quantification of a broad range of analytes
CN103037891A (zh) 2010-06-03 2013-04-10 雷蒙特亚特特拉维夫大学有限公司 治疗糖尿病的方法和能够治疗糖尿病的组合物
US20130316351A1 (en) 2010-06-07 2013-11-28 Osnat Ashur-Fabian Methods and kits for diagnosing conditions related to hypoxia
US20130097731A1 (en) 2010-06-16 2013-04-18 Futuragene Israel Ltd. Pest-resistant plants containing a combination of a spider toxin and a chitinase
EP2582842A2 (en) 2010-06-16 2013-04-24 Yissum Research Development Company of The Hebrew University of Jerusalem Method of diagnosing and treating cancer
EP2593468B1 (en) 2010-07-12 2020-06-10 The State of Israel, Ministry of Agriculture and Rural Development, Agricultural Research Organization, (A.R.O.), Volcani Center Isolated polynucleotides and methods and plants using same for regulating plant acidity
WO2012007951A1 (en) 2010-07-15 2012-01-19 Technion Research & Development Foundation Ltd. Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and glutamic acid decarboxylase (gad) autoantigenic peptides
EP2593554A2 (en) 2010-07-15 2013-05-22 Technion Research And Development Foundation Ltd. Nucleic acid construct for increasing abiotic stress tolerance in plants
CA2805478A1 (en) 2010-07-15 2012-01-19 Technion Research & Development Foundation Ltd. Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and diabetes-associated autoantigenic peptides
WO2012011113A2 (en) 2010-07-22 2012-01-26 Shai Yarkoni Regulatory immune cells with enhanced targeted cell death effect
WO2012014207A2 (en) 2010-07-27 2012-02-02 Technion Research & Development Foundation Ltd. Method for generating induced pluripotent stem cells from keratinocytes derived from plucked hair follicles
WO2012014208A2 (en) 2010-07-27 2012-02-02 Yeda Research And Development Co. Ltd. Methods and systems for assessing clonality of cell cultures
US9144585B2 (en) 2010-07-27 2015-09-29 Technion Research & Development Foundation Limited Isolated mesenchymal progenitor cells and extracellular matrix produced thereby
WO2012017439A2 (en) 2010-08-04 2012-02-09 Ramot At Tel-Aviv University Ltd. Methods of treating autoimmune diseases of the central nervous system (cns) and neurodegenerative diseases
SG187830A1 (en) 2010-08-22 2013-03-28 Univ Ramot Induced pluripotent stem cells derived from human pancreatic beta cells
WO2012025925A1 (en) 2010-08-24 2012-03-01 Rappaport Family Institute For Research In The Medical Sciences Methods of improving transplantation using sdf-1alpha
WO2012028993A2 (en) 2010-08-30 2012-03-08 Evogene Ltd. Isolated polynucleotides and polypeptides, and methods of using same for increasing nitrogen use efficiency, yield, growth rate, vigor, biomass, oil content, and/or abiotic stress tolerance
CA2810488C (en) 2010-09-07 2025-05-06 Technion Research & Development Foundation Limited NEW PROCESSES AND CULTURE MEDIA FOR THE CULTURE OF MULTIPOTENTED STEM CELLS
WO2012032519A2 (en) 2010-09-07 2012-03-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods of diagnosing parkinson's disease
WO2012032520A1 (en) 2010-09-07 2012-03-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Readthrough acetylcholinesterase (ache-r) for treating or preventing parkinson's disease
WO2012032510A1 (en) 2010-09-07 2012-03-15 Yeda Research And Development Co. Ltd. Primers for amplifying dna and methods of selecting same
KR20130105652A (ko) 2010-09-08 2013-09-25 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 안정하고 장기간의 인그래프트먼트를 위한 면역억제 약물의 조합
MX357746B (es) 2010-09-08 2018-07-23 Yeda Res And Development Co Ltd Star Uso de células t de memoria central anti-tercera parte para el tratamiento anti-leucemia/linfoma.
CN103210082A (zh) 2010-09-15 2013-07-17 雷蒙特亚特特拉维夫大学有限公司 扩增胰岛β细胞和使其再分化的方法
US20130210901A1 (en) 2010-09-20 2013-08-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method of treating neurodegenerative diseases
US8951983B2 (en) 2010-10-17 2015-02-10 Yeda Research And Development Co. Ltd. Methods and compositions for the treatment of insulin-associated medical conditions
WO2012052878A1 (en) 2010-10-19 2012-04-26 Vascular Biogenics Ltd. Isolated polynucleotides and nucleic acid constructs for directing expression of a gene-of-interest in cells
US20130216603A1 (en) 2010-10-27 2013-08-22 Nanocyte (Israel) Ltd. Pharmaceutical compositions and delivery devices comprising stinging cells or capsules
ES2688457T3 (es) 2010-10-28 2018-11-02 Yeda Research And Development Co. Ltd. Métodos de generación de anticuerpos contra metaloenzimas
BR112013010825A2 (pt) 2010-11-03 2019-09-24 Futuragene Israel Ltda plantas transgênicas com rendimentos melhorados de sacarificação e métodos para geração das mesmas
WO2012059925A2 (en) 2010-11-04 2012-05-10 Ben-Gurion University Of The Negev Research And Development Authority Acyl-coa: diacylglycerol acyltransferase 1-like gene (ptdgat1) and uses thereof
CN103298826A (zh) 2010-11-15 2013-09-11 特拉维夫大学拉莫特有限公司 用于治疗淀粉样纤维形成相关疾病的二肽类似物
EP2640404B1 (en) 2010-11-17 2017-02-22 Ben Gurion University of The Negev Research and Development Authority T-cell therapy to neurodegenerative diseases
EP2646543A4 (en) 2010-12-02 2014-09-03 Technion Res & Dev Foundation METHOD OF GENERATING CORNEAL CELLS AND CELL POPULATIONS THEREWITH
US20120183960A1 (en) 2010-12-07 2012-07-19 Enterologics, Inc. Method for identifying e. coli m-17
JP5922147B2 (ja) 2010-12-15 2016-05-24 カディマステム リミテッド 多能性幹細胞に由来するインスリン産生細胞
MX344728B (es) 2010-12-22 2017-01-05 Evogene Ltd Polinucleótidos y polipéptidos aislados, y métodos para utilizarlos para aumentar la tolerancia al estrés abiótico, rendimiento, tasa de crecimiento, vigor, biomasa, contenido de aceite y/o eficacia en el uso de nitrógeno de las plantas.
CN103533947A (zh) 2010-12-28 2014-01-22 卡梅迪斯有限公司 用于治疗和预防感染的植物提取物
CN103443270B (zh) 2011-01-20 2017-06-06 普罗塔里克斯有限公司 用于在植物和植物细胞中表达α‑半乳糖苷酶的核酸构建体
US20130316358A1 (en) 2011-01-31 2013-11-28 Yeda Research And Development Co. Ltd. Methods of diagnosing disease using overlap extension pcr
WO2012114339A1 (en) 2011-02-23 2012-08-30 Rappaport Family Institute For Research In The Medical Sciences High affinity molecules capable of binding a type a plexin receptor and uses of same
CN106978437A (zh) 2011-03-02 2017-07-25 富途锐基尼以色列有限公司 具有功能失调的t3ss蛋白的抗菌性转基因植物
EP2680864B1 (en) 2011-03-03 2019-05-08 Ramot at Tel-Aviv University Ltd. Genetically modified muscle cells which express neurotrophic factors
WO2012120500A2 (en) 2011-03-06 2012-09-13 Merck Serono S.A. Low fucose cell lines and uses thereof
US9061006B2 (en) 2011-03-08 2015-06-23 Ramot At Tel-Aviv University Ltd. Compositions and methods for diagnosing and treating phenylketonuria (PKU)
EP2685976B1 (en) 2011-03-17 2017-12-27 Tel HaShomer Medical Research Infrastructure and Services Ltd. Quinolone analogs for treating autoimmune diseases
IN2013MN01438A (da) 2011-03-17 2015-06-12 Univ Ramot
KR101903339B1 (ko) 2011-03-22 2018-10-01 플루리스템 리미티드 방사선 또는 화학적 손상을 치료하는 방법
WO2012127475A1 (en) 2011-03-24 2012-09-27 Neurim Pharmaceuticals (1991) Ltd. Neuroprotective peptides
WO2012131680A2 (en) 2011-03-28 2012-10-04 Yeda Research And Development Co. Ltd. Compositions and methods for treating inflammation
WO2012137202A1 (en) 2011-04-05 2012-10-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Composition comprising an iron indicator attached to a microparticle and uses of same for quantifying non-transferrin bound iron (ntbi) and cellular labile iron (lci)
CA2832031C (en) 2011-04-06 2019-09-17 Ramot At Tel-Aviv University Ltd. Methods of monitoring and analyzing metabolic activity profiles diagnostic and therapeutic uses of same
US9150644B2 (en) 2011-04-12 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
SG10201601537QA (en) 2011-04-15 2016-04-28 Pluristem Ltd Methods and systems for harvesting cells
US10760088B2 (en) 2011-05-03 2020-09-01 Evogene Ltd. Isolated polynucleotides and polypeptides and methods of using same for increasing plant yield, biomass, growth rate, vigor, oil content, abiotic stress tolerance of plants and nitrogen use efficiency
US9192670B2 (en) 2011-05-04 2015-11-24 Ramot At Tel-Aviv University Ltd. Regulation of amyloid beta molecular composition for the treatment of alzheimer's disease
WO2012153333A1 (en) 2011-05-09 2012-11-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Regeneration and repair of mesenchymal tissue using amelogenin
WO2012153336A2 (en) 2011-05-12 2012-11-15 Rakuto Bio Technologies Ltd. Methods and device for lightening skin complexion
WO2012156976A1 (en) 2011-05-16 2012-11-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods of producing artemisinin in non-host plants and vectors for use in same
WO2012160526A2 (en) 2011-05-23 2012-11-29 Ofir Menashe Formulations of microorganism comprising particles and uses of same
EP2715350B1 (en) 2011-05-23 2017-09-27 Yeda Research and Development Co. Ltd. Use of akt phosphorylation as a biomarker for prognosing neurodegenerative diseases and treating same
EP2714719B1 (en) 2011-05-31 2018-12-12 Hutchison Biofilm Medical Solutions Limited Dispersion and detachment of cell aggregates
WO2012164565A1 (en) 2011-06-01 2012-12-06 Yeda Research And Development Co. Ltd. Compositions and methods for downregulating prokaryotic genes
US10166295B2 (en) 2011-06-02 2019-01-01 Opko Biologics Ltd. Pegylated OXM variants
EP2720720B1 (en) 2011-06-14 2018-02-28 Yeda Research and Development Co. Ltd. Combination therapy to prevent dcis formation and progression to breast cancer
BR112013033096A2 (pt) 2011-06-23 2017-01-24 Kaiima Bio Agritech Ltd trigo mole, plantas ou partes respectivas tendo genoma multiplicado parcial ou totalmente, híbridos e produtos respectivos e métodos de geração e uso respectivos
RU2014106125A (ru) 2011-07-20 2015-08-27 Каиима Био Агритех Лтд. Растения кукурузы с частично или полностью умноженным геномом и их применения
US20130030452A1 (en) 2011-07-27 2013-01-31 Health Corporation - Rambam Devices for surgical applications
US9150858B2 (en) 2011-08-04 2015-10-06 Yeda Research And Development Co. Ltd. Micro-RNAs and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions
WO2013021389A2 (en) 2011-08-09 2013-02-14 Yeda Research And Development Co.Ltd. Downregulation of mir-7 for promotion of beta cell differentiation and insulin production
RU2014108930A (ru) 2011-08-14 2015-09-20 Каиима Био Агритех Лтд. Растения твердой пшеницы, обладающие частично или полностью умноженным геномом, и их применения
EP2753367A4 (en) 2011-09-07 2015-10-14 Yeda Res & Dev OLFACTORY SIGNATURE AND ODORING MIXTURE THEREWITH
EP2753716B1 (en) 2011-09-08 2017-11-01 Yeda Research and Development Co. Ltd. Novel risk biomarkers for lung cancer
AU2012305931B2 (en) 2011-09-08 2017-09-07 Yeda Research And Development Co. Ltd Anti third party central memory T cells, methods of producing same and use of same in transplantation and disease treatment
EP3382027A3 (en) 2011-09-13 2018-10-31 Monsanto Technology LLC Methods and compositions for weed control
US10760086B2 (en) 2011-09-13 2020-09-01 Monsanto Technology Llc Methods and compositions for weed control
US10806146B2 (en) 2011-09-13 2020-10-20 Monsanto Technology Llc Methods and compositions for weed control
US10829828B2 (en) 2011-09-13 2020-11-10 Monsanto Technology Llc Methods and compositions for weed control
MX361938B (es) 2011-09-13 2018-12-19 Monsanto Technology Llc Métodos y composiciones para el control de malezas.
WO2013040057A1 (en) 2011-09-13 2013-03-21 Monsanto Technology Llc Methods and compositions for weed control
CA2848695A1 (en) 2011-09-13 2013-03-21 Monsanto Technology Llc Methods and composition for weed control comprising inhibiting ppg oxidase
WO2013054320A1 (en) 2011-10-11 2013-04-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
AU2012325604B2 (en) 2011-10-21 2017-08-03 Augurex Life Sciences Corp. Antigens derived from citrullinated 14-3-3 and uses thereof in the diagnosis of rheumatoid arthritis
EP2771464B1 (en) 2011-10-27 2018-03-21 Yeda Research and Development Co. Ltd. Methods of treating cancer
JP6118331B2 (ja) 2011-11-03 2017-04-19 クォーク ファーマシューティカルズ インコーポレーティッドQuark Pharmaceuticals,Inc. 神経保護のための方法および組成物
US20140323549A1 (en) 2011-11-08 2014-10-30 Quark Pharmaceuticals, Inc. Methods and compositions for treating diseases, disorders or injury of the nervous system
US9736998B2 (en) 2011-11-23 2017-08-22 Danziger Dan Flower Farm Otomeria plants
WO2013076730A1 (en) 2011-11-27 2013-05-30 Yeda Research And Development Co. Ltd. Methods of regulating angiogenesis and compositions capable of same
KR20140102730A (ko) 2011-12-08 2014-08-22 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 포유류 태아 폐 세포와 이를 치료용으로 사용하는 방법
WO2013093921A1 (en) 2011-12-20 2013-06-27 Collplant Ltd. Collagen coated synthetic polymer fibers
MX370404B (es) 2011-12-22 2019-12-11 Yeda Res & Dev Uso de una terapia de combinación para inducir un injerto estable y a largo plazo.
US20130164193A1 (en) 2011-12-22 2013-06-27 Life Technologies Corporation Sequential lateral flow capillary device for analyte determination
AR089461A1 (es) 2011-12-28 2014-08-27 Kaiima Bio Agritech Ltd Una planta de sorghum cultivada que tiene un genoma parcial o totalmente multiplicado y usos de la misma
JP2015509085A (ja) 2012-01-01 2015-03-26 キュービーアイ エンタープライゼズ リミテッドQbi Enterprises Ltd. 治療剤および診断剤の選択的送達のためのendo180を標的とする粒子
WO2013114363A2 (en) 2012-01-30 2013-08-08 Yeda Research And Development Co.Ltd. Antimicrobial agents
US9603907B2 (en) 2012-02-01 2017-03-28 Protalix Ltd. Dry powder formulations of dNase I
US10184131B2 (en) 2012-02-06 2019-01-22 A.B. Seeds Ltd. Isolated polynucleotides expressing or modulating microRNAs or targets of same, transgenic plants comprising same and uses thereof
HK1202581A1 (en) 2012-02-13 2015-10-02 Gamida-Cell Ltd. Mesenchymal stem cells conditioned medium and methods of generating and using the same
EP4488289A3 (en) 2012-02-14 2025-03-19 OPKO Biologics Ltd. Long-acting coagulation factors and uses thereof
WO2013121405A1 (en) 2012-02-19 2013-08-22 Protalix Ltd. Oral unit dosage forms and uses of same for the treatment of gaucher disease
EP2844744A2 (en) 2012-02-22 2015-03-11 Brainstem Biotec Ltd. MicroRNAS FOR THE GENERATION OF ASTROCYTES
EP3401394A1 (en) 2012-02-22 2018-11-14 Exostem Biotec Ltd Generation of neural stem cells
EP2833714A1 (en) 2012-03-01 2015-02-11 The State of Israel - Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Center) Male sterile garlic plants, hybrid offspring of same and methods of generating and using same
WO2013132495A1 (en) 2012-03-07 2013-09-12 Yeda Research And Development Co. Ltd. Compositions for inhibition of quiescin sulfhydryl oxidase (qsox1) and uses of same
WO2013140389A1 (en) 2012-03-22 2013-09-26 Ramot At Tel-Aviv University Ltd. Plif multimeric peptides and uses thereof
EP2839015B1 (en) 2012-04-18 2020-04-29 Ramot at Tel-Aviv University Ltd. Lipidated glycosaminoglycan particles for the delivery of nucleic acids
BR112014025951A2 (pt) 2012-04-19 2017-07-11 Opko Biologics Ltd variantes de oxintomodulina de longa ação e métodos de produção do mesmo
US9439942B2 (en) 2012-04-24 2016-09-13 Biokine Therapeutics Ltd. Peptides and use thereof in the treatment of large cell lung cancer
WO2013168164A1 (en) 2012-05-09 2013-11-14 Yeda Research And Development Co. Ltd. Variants of tace pro-domain as tnf-a inhibitor and their medical use
US8865158B2 (en) 2012-05-22 2014-10-21 Ramot At Tel-Aviv University Ltd. Bacteriophages for reducing toxicity of bacteria
EP2855521A4 (en) 2012-05-24 2016-03-02 Mountgate Group Ltd COMPOSITIONS AND METHODS RELATED TO PREVENTING AND TREATING TOLL WUTINFECTION
MX360866B (es) 2012-05-24 2018-11-09 A B Seeds Ltd Composiciones y métodos para silenciar la expresión genética.
US9731048B2 (en) 2012-06-03 2017-08-15 Ben-Gurion University Of The Negev Research And Development Authority Functionalized titanium binding peptides and implants coated with same
MX362432B (es) 2012-06-04 2019-01-17 Opko Biologics Ltd Variantes de oxm pegilada.
US10023474B2 (en) 2012-07-03 2018-07-17 Nanospun Technologies Ltd. Methods for adsorption and biodegradation of petroleum
US9567569B2 (en) 2012-07-23 2017-02-14 Gamida Cell Ltd. Methods of culturing and expanding mesenchymal stem cells
US9175266B2 (en) 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
DK2880155T3 (da) 2012-07-29 2019-07-15 Yeda Res & Dev Anvendelse af den reduktive glycinvej til generering af formatotrofiske og autotrofiske mikroorganismer
JP6340366B2 (ja) 2012-07-31 2018-06-06 イェダ リサーチ アンド デベロップメント カンパニー リミテッド 運動ニューロン疾患を診断および処置する方法
DK2880151T3 (da) 2012-08-06 2020-08-17 Brainstorm Cell Therapeutics Ltd Fremgangsmåder til frembringelse af mesenkymale stemceller, som udskiller neurotrofiske faktorer
WO2014033723A1 (en) 2012-09-03 2014-03-06 A.B. Seeds Ltd. Method of improving abiotic stress tolerance of plants and plants generated thereby
US10543278B2 (en) 2012-09-12 2020-01-28 Ramot At Tel-Aviv University Ltd. Immunoparticles and methods of generating and using same
WO2014057490A1 (en) 2012-10-09 2014-04-17 Ramot At Tel-Aviv University Ltd. Methods and kits for predicting prognosis of cancer using soluble mortalin in blood
CN104918639B (zh) 2012-10-22 2018-01-26 萨拜格Rfa公司 用于将治疗剂递送到活细胞和细胞核中的系统
WO2014064682A1 (en) 2012-10-24 2014-05-01 Yeda Research And Development Co. Ltd. Combinations of epidermal growth factor receptor targeting antibodies for treating cancer
WO2014068553A1 (en) 2012-10-29 2014-05-08 Yeda Research And Development Co. Ltd. Aptamers, multimeric aptamers and uses thereof
EA033788B1 (ru) 2012-11-20 2019-11-26 Opko Biologics Ltd Способ увеличения гидродинамического объема полипептида путем присоединения карбоксиконцевого пептида гонадотропина
WO2015079413A2 (en) 2013-11-28 2015-06-04 Yeda Research And Development Co. Ltd. Synaptojanin-2 inhibitors and uses thereof
CN104822390A (zh) 2012-11-29 2015-08-05 耶达研究及发展有限公司 预防肿瘤转移、癌症治疗和预后及鉴定为推定转移抑制剂的试剂的方法
UY35252A (es) 2013-01-01 2014-07-31 Seeds Ltd Ab MÉTODOS PARA INTRODUCIR dsRNA EN SEMILLAS DE PLANTAS PARA MODULAR LA EXPRESIÓN GENÉTICA
US10683505B2 (en) 2013-01-01 2020-06-16 Monsanto Technology Llc Methods of introducing dsRNA to plant seeds for modulating gene expression
WO2014108854A1 (en) 2013-01-09 2014-07-17 Fusimab Ltd. Monospecific anti-hgf and anti-ang2 antibodies and bispecific anti-hgf/anti-ang2 antibodies
WO2014108850A2 (en) 2013-01-09 2014-07-17 Yeda Research And Development Co. Ltd. High throughput transcriptome analysis
EP3431985A1 (en) 2013-01-17 2019-01-23 Novellusdx Ltd. Methods and systems for identifying patient specific driver mutations
WO2014118785A1 (en) 2013-02-04 2014-08-07 Ramot At Tel-Aviv University Ltd. Generation of cytotoxic tumor specific cell lines and uses thereof
CA2902727C (en) 2013-03-06 2020-08-18 Protalix Ltd. Use of plant cells expressing a tnfalpha polypeptide inhibitor in therapy
US20160017020A1 (en) 2013-03-06 2016-01-21 Protalix Ltd. Chimeric polypeptides, polynucleotides encoding same, cells expressing same and methods of producing same
BR112015023051A2 (pt) 2013-03-13 2017-11-14 Monsanto Technology Llc método para controle de ervas daninhas, composição herbicida, cassete de expressão microbiano e método de produção de polinucleotídeo
US10612019B2 (en) 2013-03-13 2020-04-07 Monsanto Technology Llc Methods and compositions for weed control
US10568328B2 (en) 2013-03-15 2020-02-25 Monsanto Technology Llc Methods and compositions for weed control
ES2883580T3 (es) 2013-03-21 2021-12-09 Collplant Ltd Composiciones que comprenden colágeno y PRP para la regeneración de tejidos y su método de producción
WO2014153394A1 (en) 2013-03-21 2014-09-25 Genisphere, Llc Cellular delivery of dna intercalating agents
EP2978439B1 (en) 2013-03-24 2017-08-16 Biokine Therapeutics Ltd. A combination of a cxcr4 antagonist and cytarabine for use in treating myeloid leukemia
CN105377289A (zh) 2013-04-21 2016-03-02 耶达研究及发展有限公司 用于下调Bcl-xL和/或Bcl-w的活性和/或量的试剂
JP2016521971A (ja) 2013-04-23 2016-07-28 イェダ リサーチ アンド ディベロップメント カンパニー リミテッド 単離ナイーブ型多能性幹細胞およびそれを発生させる方法関連出願本出願は、米国特許法119条第(e)項に基づき、2014年1月29日出願の米国特許仮出願第61/932,935号、2013年9月17日出願の米国特許仮出願第61/878,769号、および2013年4月23日出願の米国特許仮出願第61/814,920号の優先権を主張する。また、本出願は、同時に提出された同出願人による同時係属出願である、YaqubHANNA、NoaNOVERSHTERN、およびYoachRAISによる米国特許出願(発明の名称「単離ナイーブ型多能性幹細胞およびそれを発生させる方法(ISOLATEDNAIVEPLURIPOTENTSTEMCELLSANDMETHODSOFGENERATINGSAME)」)(代理人事件記録簿第58870号)にも関する。上記出願の内容はその全体を参考として本明細書に組み込む。
CN105555796B (zh) 2013-04-25 2019-09-17 耶达研究及发展有限公司 抑制肽对治疗炎性疾病的用途
US20160115231A1 (en) 2013-05-21 2016-04-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Treatment of mast cell related pathologies
WO2014191995A2 (en) 2013-05-27 2014-12-04 Rakuto Bio Technologies Ltd. Enzymatic system-containing cosmetic compositions
ES2938044T3 (es) 2013-06-24 2023-04-04 Univ Ramot Estructura a base de epiplón y sistema de suministro
EP3030663B1 (en) 2013-07-19 2019-09-04 Monsanto Technology LLC Compositions and methods for controlling leptinotarsa
US9850496B2 (en) 2013-07-19 2017-12-26 Monsanto Technology Llc Compositions and methods for controlling Leptinotarsa
WO2015015489A1 (en) 2013-07-30 2015-02-05 Biolinerx Ltd. Antibody for treating diabetes and autoimmune diseases
EP3039030B1 (en) 2013-08-29 2018-09-19 Yeda Research and Development Co. Ltd. Selective inhibitors of alpha2 isoform of na,k-atpase and use for reduction of intra-ocular pressure
IL228284A (en) 2013-09-03 2016-12-29 Technion Res & Dev Foundation Implants from cellular scaffolding and blood vessel stalk
WO2015033343A1 (en) 2013-09-03 2015-03-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Compositions and methods for expressing recombinant polypeptides
WO2015033344A1 (en) 2013-09-05 2015-03-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods and kits for inhibiting pathogenicity of group a streptococcus (gas) or group g streptococcus (ggs)
WO2015037009A1 (en) 2013-09-16 2015-03-19 Plexicure Ltd. Isolated proteins capable of binding plexin-a4 and methods of producing and using same
US9695402B2 (en) 2013-09-17 2017-07-04 Yeda Research And Development Co. Ltd. ERK-derived peptides and uses thereof
CN105960453A (zh) 2013-10-01 2016-09-21 卡迪马干细胞有限公司 从人多能干细胞定向分化星形胶质细胞用于肌萎缩侧索硬化(als)的治疗和药物筛选
EP3055066A4 (en) 2013-10-07 2017-06-14 Yeda Research and Development Co., Ltd. Microfluidic device for analyzing gene expression
RU2746943C2 (ru) 2013-10-21 2021-04-22 Опко Байолоджикс Лтд. Полипептиды длительного действия и способы их получения и введения
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
EP3060656A1 (en) 2013-10-24 2016-08-31 Yeda Research and Development Co., Ltd. Polynucleotides encoding brex system polypeptides and methods of using same
CA2928315C (en) 2013-10-31 2023-03-21 Biokine Therapeutics Ltd. Methods of treating acute myeloid leukemia with a flt3 mutation
AU2014341879B2 (en) 2013-11-04 2020-07-23 Greenlight Biosciences, Inc. Compositions and methods for controlling arthropod parasite and pest infestations
CA2925698C (en) 2013-11-28 2021-11-09 Tel Hashomer Medical Research Infrastructure And Services Ltd. Rna polymerase i inhibitors and uses thereof
UA119253C2 (uk) 2013-12-10 2019-05-27 Біолоджикс, Інк. Спосіб боротьби із вірусом у кліща varroa та у бджіл
WO2015087327A1 (en) 2013-12-10 2015-06-18 Yeda Research And Development Co. Ltd. Use of enzymes which catalyze pyruvate synthesis from formate and acetyl-coa and bacteria expressing same
WO2015108982A2 (en) 2014-01-15 2015-07-23 Monsanto Technology Llc Methods and compositions for weed control using epsps polynucleotides
WO2015114633A1 (en) 2014-01-30 2015-08-06 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Ltd. Actin binding peptides and compositions comprising same for inhibiting angiogenes is and treating medical conditions associated with same
CA2937992A1 (en) 2014-02-03 2015-08-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method of eliminating stem cells
WO2015118537A2 (en) 2014-02-05 2015-08-13 Yeda Research And Development Co. Ltd. Micro-rnas and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions
US10066014B2 (en) 2014-02-06 2018-09-04 Yeda Research And Development Co. Ltd. Anti CD84 antibodies, compositions comprising same and uses thereof
WO2015118547A1 (en) 2014-02-10 2015-08-13 Protalix Ltd. Method of maintaining disease stability in a subject having gaucher's disease
JP6628253B2 (ja) 2014-02-11 2020-01-08 ブレインストーム セル セラペウティクス リミテッド 細胞の適性を判定する方法
US20170067894A1 (en) 2014-03-03 2017-03-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method and device for detection of pseudomonas aeruginosa
EP2923709A1 (en) 2014-03-28 2015-09-30 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Multi-component-multistage malaria vaccine
WO2015153339A2 (en) 2014-04-01 2015-10-08 Monsanto Technology Llc Compositions and methods for controlling insect pests
EP3129075B1 (en) 2014-04-10 2024-09-18 Bonus Therapeutics Ltd. Bone repair compositions
EP3132055A2 (en) 2014-04-14 2017-02-22 Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. A method and kit for determining the tissue or cell origin of dna
WO2015159295A1 (en) 2014-04-17 2015-10-22 Yeda Research And Development Co. Ltd. Methods and kits for analyzing dna binding moieties attached to dna
US11427647B2 (en) 2014-04-27 2022-08-30 Famewave Ltd. Polynucleotides encoding humanized antibodies against CEACAM1
CN106573977B (zh) 2014-04-27 2020-08-07 菲姆威有限公司 针对ceacam1的人源化抗体
EP3058085B1 (en) 2014-04-28 2021-02-17 Yeda Research and Development Co., Ltd. Microbiome response to agents
CN108064133A (zh) 2014-05-04 2018-05-22 佛利斯特创新有限公司 用于蚊虫控制的组合物和所述组合物的用途
US10294482B2 (en) 2014-05-22 2019-05-21 Yeda Research And Development Co. Ltd. Recombinant microorganisms capable of carbon fixation
US20170253881A1 (en) 2014-06-02 2017-09-07 Technion Research & Development Foundation Limited Compositions and methods of selectively inhibiting irp1 and treating inflammation
WO2015186128A1 (en) 2014-06-02 2015-12-10 Kadimastem Ltd. Methods of inducing myelination and maturation of oligodendrocytes
CN106795515B (zh) 2014-06-23 2021-06-08 孟山都技术公司 用于经由rna干扰调控基因表达的组合物和方法
WO2015198320A1 (en) 2014-06-24 2015-12-30 Insight Biopharmaceuticals Ltd. Methods of purifying antibodies
CN106537148B (zh) 2014-06-25 2019-10-11 泰尔哈绍梅尔医学研究基础设施和服务有限公司 癌症干细胞的鉴定及其用于诊断和治疗的用途
US11807857B2 (en) 2014-06-25 2023-11-07 Monsanto Technology Llc Methods and compositions for delivering nucleic acids to plant cells and regulating gene expression
US10583084B2 (en) 2014-06-26 2020-03-10 Ramot At Tel-Aviv University Ltd. Liposomal formulations for delivery of nucleic acids
WO2016005985A2 (en) 2014-07-09 2016-01-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method for reprogramming cells
ES2799404T3 (es) 2014-07-15 2020-12-17 Yissum Research And Development Company Of The Hebrew Univ Of Jerusalem Ltd Polipéptidos de CD44 aislados y usos de los mismos
EP3172562B1 (en) 2014-07-21 2019-03-13 Novellusdx Ltd. Methods and systems for determining oncogenic index of patient specific mutations
EP3172340B1 (en) 2014-07-21 2019-02-20 Novellusdx Ltd. Methods for determining drug response of patient specific mutations
CN106604993A (zh) 2014-07-29 2017-04-26 孟山都技术公司 用于控制昆虫害虫的组合物和方法
US11920164B2 (en) 2014-07-30 2024-03-05 Yeda Research And Development Co. Ltd. Media for culturing naive human pluripotent stem cells
BR112017002884A2 (pt) 2014-08-14 2018-01-30 Memed Diagnostics Ltd ?análise computacional de dados biológicos por meio do uso de variedade e hiperplano?
WO2016030899A1 (en) 2014-08-28 2016-03-03 Yeda Research And Development Co. Ltd. Methods of treating amyotrophic lateral scleroses
AU2015313811A1 (en) 2014-09-08 2017-04-06 Yeda Research And Development Co. Ltd. Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (TKI)
CA2959716A1 (en) 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Anti-her3 antibodies and uses of same
EP2992895A1 (en) 2014-09-08 2016-03-09 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Three-component-multistage malaria vaccine
CA2972739A1 (en) 2014-09-11 2016-03-17 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Methods of producing mogrosides and compositions comprising same and uses thereof
IL234638A0 (en) 2014-09-14 2014-12-02 Yeda Res & Dev NMDA receptor antagonists for the treatment of Gaucher disease
CN106999608A (zh) 2014-09-21 2017-08-01 耶路撒冷希伯来大学伊森姆研究发展公司 为了治疗脂质相关病症而下调mir‑132
DE102015220401B4 (de) 2014-10-20 2022-12-29 Gen-Probe Incorporated Erythrozyten-Lyselösung
US10570368B2 (en) 2014-11-13 2020-02-25 Enzootic Holdings Ltd. Functional sex-reversal of decapod crustacean females
JP2017533723A (ja) 2014-11-17 2017-11-16 イェダ リサーチ アンド ディベロップメント カンパニー リミテッドYeda Research And Development Co.Ltd. マイクロバイオーム解析方法
WO2016079736A2 (en) 2014-11-17 2016-05-26 Yeda Research And Development Co. Ltd. Methods of treating diseases related to mitochondrial function
WO2016079739A2 (en) 2014-11-20 2016-05-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Compositions and methods for producing polypeptides with a modified glycosylation pattern in plant cells
WO2016084088A1 (en) 2014-11-26 2016-06-02 Ramot At Tel-Aviv University Ltd. Targeted elimination of bacterial genes
EP3224363B1 (en) 2014-11-27 2021-11-03 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Nucleic acid constructs for genome editing
HRP20230405T8 (hr) 2014-12-10 2023-09-29 Opko Biologics Ltd. Metode proizvodnje dugo djelujućih ctp-modificiranih polipeptida hormona rasta
WO2016092555A2 (en) 2014-12-11 2016-06-16 Yeda Research And Development Co. Ltd. Isolated phosphotriesterase polypeptides, polynucleotides encoding same and uses thereof in treating or preventing organophosphate exposure associated damage
CN111624345A (zh) 2014-12-11 2020-09-04 米密德诊断学有限公司 用于诊断多种感染的标记组合及其使用方法
WO2016103269A1 (en) 2014-12-23 2016-06-30 Ramot At Tel-Aviv University Ltd. Populations of neural progenitor cells and methods of producing and using same
KR20170115514A (ko) 2014-12-30 2017-10-17 셀 큐어 뉴로사이언시스 리미티드 Rpe 세포 집단 및 이를 생성하는 방법
WO2016108240A1 (en) 2014-12-30 2016-07-07 Cell Cure Neurosciences Ltd. Assessing retinal pigment epithelial cell populations
CN114533761A (zh) 2014-12-30 2022-05-27 细胞治疗神经科学有限公司 治疗视网膜疾病的方法
IL253208B2 (en) 2015-01-04 2023-03-01 Protalix Ltd Converted DNase and its uses
WO2016116935A1 (en) 2015-01-21 2016-07-28 Yeda Research And Development Co. Ltd. Use of rasa2 as a prognostic and therapeutic marker for melanoma
CN108064288B (zh) 2015-01-22 2021-11-26 孟山都技术公司 用于控制叶甲属的组合物和方法
EP3261612A1 (en) 2015-02-26 2018-01-03 Yeda Research and Development Co. Ltd Method of promoting hair growth
EP3268475B1 (en) 2015-03-11 2020-10-21 Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. Decoy oligonucleotides for the treatment of diseases
IL237852A0 (en) 2015-03-19 2016-03-24 Yeda Res & Dev Antibodies against amphigoline, medical preparations containing them and their use
AU2016243124A1 (en) 2015-03-27 2017-11-02 University Of Southern California CAR T-cell therapy directed to LHR for the treatment of solid tumors
WO2016157175A1 (en) 2015-03-27 2016-10-06 Yeda Research And Development Co. Ltd. Methods of treating motor neuron diseases
CN107771217A (zh) 2015-03-31 2018-03-06 耶达研究及发展有限公司 谷氨酸草酰乙酸转氨酶1 (got1)、制剂和产生它们的方法及其用途
EP3277260B1 (en) 2015-04-01 2021-05-12 The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Center) Erodium crassifolium l'her plant extracts and uses thereof
AU2016245434B2 (en) 2015-04-07 2020-10-29 Ela Pharma Ltd Compositions for treating and/or preventing cell or tissue necrosis specifically targeting Cathepsin C and/or CELA1 and/or CELA3A and/or structurally related enzymes thereto
EP3081575A1 (en) 2015-04-12 2016-10-19 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Anti-plasmodium parasite antibodies
CA2986202C (en) 2015-04-27 2023-08-22 The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center Egr1 targeting molecules for the treatment of inflammatory and hyperproliferative conditions
ES2911341T3 (es) 2015-04-29 2022-05-18 The State Of Israel Ministry Of Agriculture & Rural Development Agricultural Res Organization Aro Vo Composiciones antifitopatogénicas
WO2016174652A1 (en) 2015-04-30 2016-11-03 Technion Research & Development Foundation Limited Chimeric antigen receptors and methods of their use
EP3292219B9 (en) 2015-05-04 2022-05-18 Ramot at Tel-Aviv University Ltd. Methods and kits for fragmenting dna
EP3294280A1 (en) 2015-05-11 2018-03-21 Yeda Research and Development Co., Ltd. Citrin inhibitors for the treatment of cancer
EP3298141A4 (en) 2015-05-17 2019-01-09 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER
WO2016185457A1 (en) 2015-05-19 2016-11-24 Yeda Research And Development Co. Ltd. Methods of promoting lymphangiogenesis
WO2016185481A2 (en) 2015-05-20 2016-11-24 Yeda Research And Development Co. Ltd. Method of targeting senescent cells
BR112017024928A2 (pt) 2015-05-21 2018-07-31 Yeda Research And Development Co Ltd Métodos para prevenção da diabetes ou pré- diabetes em um indivíduo, para melhoria da resposta à glicose em um indivíduo com intolerância à glicose, para manutenção da resposta à glicose em um indivíduo com tolerância à glicose e para melhoria da saúde de um indivíduo, composição probiótica e composição farmacêutica
JP2018517697A (ja) 2015-05-29 2018-07-05 オプコ バイオロジクス リミテッド ペグ化オキシントモジュリン変異体
EP3302053B1 (en) 2015-06-02 2021-03-17 Monsanto Technology LLC Compositions and methods for delivery of a polynucleotide into a plant
WO2016196782A1 (en) 2015-06-03 2016-12-08 Monsanto Technology Llc Methods and compositions for introducing nucleic acids into plants
JP7010473B2 (ja) 2015-06-04 2022-02-10 ユニバーシティ オブ サザン カリフォルニア Lym-1およびlym-2標的化car細胞免疫療法
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
WO2016203476A1 (en) 2015-06-18 2016-12-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods and compositions for diagnosing and treating urothelial cancer
ES2917884T3 (es) 2015-06-18 2022-07-12 Yeda Res & Dev Protocolos de acondicionamiento y uso de los mismos para la regeneración de tejidos
ES2893616T3 (es) 2015-06-19 2022-02-09 Opko Biologics Ltd Factores de coagulación de acción prolongada y métodos para la producción de los mismos
IL274572B2 (en) 2015-07-16 2024-01-01 Biolinerx Ltd Compositions and methods for treating cancer
JP7057748B2 (ja) 2015-07-16 2022-04-20 イェダ リサーチ アンド ディベロップメント カンパニー リミテッド 遺伝子改変された抗第三者中枢性メモリーt細胞および免疫療法におけるその使用
WO2017013648A1 (en) 2015-07-19 2017-01-26 Yeda Research And Development Co. Ltd. SELECTIVE INHIBITORS OF Alpha2-CONTAINING ISOFORMS OF Na,K-ATPase AND USE THEREOF FOR REDUCTION OF INTRAOCULAR PRESSURE
BR112018001310A2 (en) 2015-07-22 2018-09-11 Phytopharma International Ltd. bee-ingestible compositions, methods of use thereof for the production of honey and honey produced by these
WO2017017686A1 (en) 2015-07-29 2017-02-02 Hadasit Medical Research Services And Development Ltd. Large scale production of retinal pigment epithelial cells
ES2965461T3 (es) 2015-08-03 2024-04-15 Biokine Therapeutics Ltd Inhibidor de CXCR4 para el tratamiento del cáncer
EP3332009A1 (en) 2015-08-04 2018-06-13 Yeda Research and Development Co., Ltd. Methods of screening for riboswitches and attenuators
WO2017021973A1 (en) 2015-08-05 2017-02-09 Cell Cure Neurosciences Ltd. Preparation of retinal pigment epithelium cells
EP3331995A1 (en) 2015-08-05 2018-06-13 Cell Cure Neurosciences Ltd. Preparation of photoreceptors for the treatment of retinal diseases
WO2017025963A1 (en) 2015-08-10 2017-02-16 The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center Methods and pharmaceutical compositions for improving wound healing using cd24
US20180237790A1 (en) 2015-08-13 2018-08-23 Forrest Innovation Ltd. Formulations and compositions for delivery of nucleic acids to plant cells
WO2017033188A1 (en) 2015-08-24 2017-03-02 Yeda Research And Development Co. Ltd. Algal oil and biofuel and methods of producing same
US10765706B2 (en) 2015-09-03 2020-09-08 University Of South Florida Method of stem cell delivery into the brain during chronic disease using blood brain barrier permeabilizers
WO2017042814A1 (en) 2015-09-10 2017-03-16 Yeda Research And Development Co. Ltd. Use of perforin positive immature dendritic cells in disease treatment
WO2017072757A1 (en) 2015-10-25 2017-05-04 Yeda Research And Development Co. Ltd. Antibodies targeting quiescin sulfhydryl oxidase (qsox1) and uses of same
US12188047B2 (en) 2015-10-26 2025-01-07 Hadasit Medical Research Services And Development Ltd. Preparation of retinal pigment epithelium cells
WO2017072773A1 (en) 2015-10-27 2017-05-04 Ilana Nathan Compositions comprising cannabidiol and second therapeutic agents for the treatment of cancer
IL242380A0 (en) 2015-10-29 2016-02-01 Yeda Res & Dev A method of inducing cardiomyocytes proliferation and treating heart diseases
EP3370791A1 (en) 2015-11-03 2018-09-12 Ariel-University Research and Development Company Ltd. Compositions for regeneration and repair of neural tissue
WO2017081689A1 (en) 2015-11-11 2017-05-18 Ramot At Tel-Aviv University Ltd. Methods of detecting 5-hydroxymethylcytosine and diagnosing of cancer
BR112018010946A2 (en) 2015-11-30 2018-12-04 Kadimastem Ltd pancreatic endocrine cell enrichment method, pancreatic endocrine cell enriched population, diabetes treatment method and insulin production beta cell preparation method
EP3176183A1 (en) 2015-12-02 2017-06-07 Yeda Research and Development Co. Ltd Compositions and methods for treating cancer not resistant to a tyrosine kinase inhibitor (tki)
US11213609B2 (en) 2015-12-16 2022-01-04 Ramot At Tel-Aviv University Ltd. Particles comprising decellularized omentum
WO2017115367A1 (en) 2015-12-28 2017-07-06 The National Institute for Biotechnology in the Negev Ltd. Composition and method for treating amyotrophic lateral sclerosis
JP2019505511A (ja) 2016-01-06 2019-02-28 イェダ リサーチ アンド ディベロップメント カンパニー リミテッドYeda Research And Development Co.Ltd. 悪性疾患、自己免疫疾患および炎症性疾患を処置するための組成物および方法
WO2017122203A1 (en) 2016-01-11 2017-07-20 Technion Research & Development Foundation Limited Methods of determining prognosis of sepsis and treating same
CN109068605B (zh) 2016-01-21 2022-11-11 以色列国家农业和农村发展农业研究组织沃尔坎尼中心 单性结实植物及其产生方法
IL243838A (en) 2016-01-28 2017-07-31 Sp Nano Ltd The composition containing sp1 protein and carbon nanoparticles and its uses
IL243839B (en) 2016-01-28 2018-01-31 Sp Nano Ltd Conductive wires
WO2017130205A1 (en) 2016-01-31 2017-08-03 Hadasit Medical Research Services And Development Ltd. Autosomal-identical pluripotent stem cell populations having non-identical sex chromosomal composition and uses thereof
AU2017214733B2 (en) 2016-02-04 2022-09-29 Yeda Research And Development Co. Ltd. Peptides and use of same in the treatment of diseases, disorders or conditions associated with a mutant p53
WO2017138008A2 (en) 2016-02-14 2017-08-17 Yeda Research And Development Co. Ltd. Methods of modulating protein exocytosis and uses of same in therapy
EP3414346B1 (en) 2016-02-14 2019-11-13 Yeda Research and Development Co. Ltd. Microbiome-based diagnosis, prediction and treatment of relapsing obesity
US20190246638A1 (en) 2016-02-16 2019-08-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd, Non-protein phenylalanine analogues for inhibiting cyanobacteria and plant growth
IL260983B (en) 2016-02-19 2022-07-01 Genisphere Llc Nucleic acid carriers and methods of medical use
WO2017145162A1 (en) 2016-02-23 2017-08-31 Chaya Brodie Generation of cancer stem cells and use thereof
MX2018010445A (es) 2016-03-01 2019-10-17 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Anticuerpos especificos del receptor de poliovirus humano (rvp).
IL287757B (en) 2016-03-03 2022-07-01 Memed Diagnostics Ltd Analyzing rna for diagnosing infection type
US20190216891A1 (en) 2016-03-06 2019-07-18 Yeda Research And Development Co., Ltd. Method for modulating myelination
IL244649A0 (en) 2016-03-17 2016-06-30 Yeda Res & Dev Methods for the isolation of barrel-like proteases and the identification of peptides that are cleaved by Alidan
EP3440461A4 (en) 2016-04-06 2019-11-06 Technion Research & Development Foundation Limited INFILTRATING IMMUNEAN PARTS FOR PREDICTING AN ANTI-TNF ANSWER IN THICK DARM BIOPSIA
US10421785B2 (en) 2016-04-11 2019-09-24 Bar-Ilan University Delta receptor agonist peptides and use thereof
CA3021914C (en) 2016-04-27 2024-04-30 Gen-Probe Incorporated Blood cell lysis reagent
WO2017203520A1 (en) 2016-05-22 2017-11-30 Yeda Research And Development Co. Ltd. Methods of using pulmonary cells for transplantation and induction of tolerance
IL245861A0 (en) 2016-05-25 2016-09-04 Yeda Res & Dev Use of substances to treat drug-resistant tumors
WO2017208247A1 (en) 2016-06-02 2017-12-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Assay for the removal of methyl-cytosine residues from dna
EP3464322B1 (en) 2016-06-05 2023-04-05 Tel HaShomer Medical Research Infrastructure and Services Ltd. Novel molecules for the treatment of inflammation
EP3468610A1 (en) 2016-06-09 2019-04-17 OPKO Biologics Ltd. Long-acting oxyntomodulin formulation and methods of producing and administering same
WO2017221225A1 (en) 2016-06-19 2017-12-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Screening for chemotherapy resistance in human haploid cells
MX2019000022A (es) 2016-06-27 2019-09-18 Yeda Res & Dev Células veto generadas a partir de linfocitos t de memoria.
EP3482200B1 (en) 2016-07-10 2022-05-04 Memed Diagnostics Ltd. Protein signatures for distinguishing between bacterial and viral infections
EP3482201B1 (en) 2016-07-10 2022-12-14 Memed Diagnostics Ltd. Early diagnosis of infections
IL246722A0 (en) 2016-07-11 2016-09-29 Yeda Res & Dev Combination therapy to increase endogenous nitric oxide (no) synthesis
KR20190038833A (ko) 2016-07-11 2019-04-09 보누스 테라퓨틱스 리미티드 조직 재생용 세포 조성물
MY206271A (en) 2016-07-11 2024-12-06 Opko Biologics Ltd Long-acting coagulation factor vii and methods of producing same
IL302693B2 (en) 2016-07-11 2025-10-01 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Methods and systems for growing cells in culture
EP4434516A3 (en) 2016-07-18 2025-02-26 Ramot at Tel-Aviv University Ltd. Modular platform for targeted therapeutics
US20190203270A1 (en) 2016-07-24 2019-07-04 Yeda Research And Development Co., Ltd. Methods and kits for analyzing dna binding moieties attached to dna
ES2965761T3 (es) 2016-08-08 2024-04-16 Tech Innovation Momentum Fund Israel Limited Partnership Sistemas bacterianos para el análisis de polipéptidos ubiquitilados
US10633706B2 (en) 2016-08-10 2020-04-28 Ramot At Tel-Aviv University Ltd. Analysis of methylation status and copy number
US12205677B2 (en) 2016-08-10 2025-01-21 Memed Diagnostics Ltd. System and method for analysis of biological data
SG11201901272WA (en) 2016-08-14 2019-03-28 Univ Ramot Mesenchymal cell-derived exosomes to treat neurological disorders
IL247368A0 (en) 2016-08-18 2016-11-30 Yeda Res & Dev Diagnostic and therapeutic uses of exosomes
WO2018037416A1 (en) 2016-08-25 2018-03-01 Yeda Research And Development Co. Ltd. Methods and compositions for treating autoimmune diseases
PE20190839A1 (es) 2016-08-28 2019-06-17 The State Of Israel Ministry Of Agriculture And Rural Development Agricultural Res Organization Aro Metodo para controlar infecciones fungicas en plantas
EP3510047A1 (en) 2016-09-07 2019-07-17 Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. Anti-nkp46 antibodies and therapeutic use of same
EP3512943B1 (en) 2016-09-14 2023-04-12 Yeda Research and Development Co. Ltd. Crisp-seq, an integrated method for massively parallel single cell rna-seq and crispr pooled screens
WO2018060998A1 (en) 2016-09-29 2018-04-05 Memed Diagnostics Ltd. Methods of prognosis and treatment
IL248468A0 (en) 2016-10-13 2017-01-31 Technion Res & Dev Foundation Use of caspase-3 inhibitors and caspase-3 activators in the manufacture of medicament for treating cancer and wound healing
IL248385A0 (en) 2016-10-18 2017-02-01 Yeda Res & Dev Treatment of circadian rhythm disorder
EP3538651A1 (en) 2016-11-10 2019-09-18 Yeda Research and Development Co., Ltd. Phosphotriesterases for treating or preventing organophosphate exposure associated damage
CN110234765A (zh) 2016-11-28 2019-09-13 耶达研究及发展有限公司 分离的多核苷酸和多肽及使用它们来表达感兴趣的表达产物的方法
US20190343782A1 (en) 2016-11-30 2019-11-14 Yeda Research And Development Co. Ltd. Methods of treating liver toxicity and disorders
SG11201810936VA (en) 2016-12-01 2019-01-30 Univ Ramot Combined treatment for nerve injuries
CN110392736A (zh) 2017-01-18 2019-10-29 耶达研究及发展有限公司 遗传修饰的反抑细胞及其在免疫治疗中的用途
WO2018138668A1 (en) 2017-01-25 2018-08-02 Mor Research Applications Ltd. Methods of diagnosing malignant diseases
IL250479A0 (en) 2017-02-06 2017-03-30 Sorek Rotem Genetically engineered cells expressing a disarm system that confers resistance to phages and methods for their production
CA3052872A1 (en) 2017-02-08 2018-08-16 Hadasit Medical Research Services And Development Ltd. Photoreceptor cells for the treatment of retinal diseases
IL250916A0 (en) 2017-03-02 2017-06-29 Geiger Benjamin Methods for growing t cells in culture and their use
WO2018167780A1 (en) 2017-03-12 2018-09-20 Yeda Research And Development Co. Ltd. Methods of prognosing and treating cancer
WO2018167778A1 (en) 2017-03-12 2018-09-20 Yeda Research And Development Co. Ltd. Methods of diagnosing and prognosing cancer
EP3595687A1 (en) 2017-03-16 2020-01-22 Lineage Cell Therapeutics, Inc. Methods for measuring therapeutic effects of retinal disease therapies
HRP20231499T1 (hr) 2017-04-05 2024-03-01 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Ex-vivo sustav kulture i metode korištenja istog
IL252151A0 (en) 2017-05-07 2017-07-31 Fainzilber Michael Treatment of stress disorders
JP7445429B2 (ja) 2017-05-10 2024-03-07 アリエル サイエンティフィック イノベーションズ リミテッド 抗体の精製法
ES2939298T3 (es) 2017-05-21 2023-04-20 Medical Res Infrastructure & Health Services Fund Tel Aviv Medical Ct Combinación de marcadores para el diagnóstico del cáncer
US20200172604A1 (en) 2017-05-23 2020-06-04 Technion Research & Development Foundation Limited Agents which inhibit gads dimerization and methods of use thereof
GB201708665D0 (en) 2017-05-31 2017-07-12 Tropic Biosciences Uk Ltd Compositions and methods for increasing extractability of solids from coffee beans
GB201708662D0 (en) 2017-05-31 2017-07-12 Tropic Biosciences Uk Ltd Compositions and methods for increasing shelf-life of banana
EP3630973A1 (en) 2017-05-31 2020-04-08 Tropic Biosciences UK Limited Methods of selecting cells comprising genome editing events
WO2018229764A1 (en) 2017-06-13 2018-12-20 Yeda Research And Development Co. Ltd. Treatment of advanced or progressive multiple sclerosis
US11466323B2 (en) 2017-07-13 2022-10-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Dual-probe digital droplet PCR strategy for specific detection of tissue-specific circulating DNA molecules
EP3652344A1 (en) 2017-07-13 2020-05-20 Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. Dna targets as tissue-specific methylation markers
US20200165671A1 (en) 2017-07-13 2020-05-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Detecting tissue-specific dna
IL253642A0 (en) 2017-07-24 2017-09-28 Seger Rony Combined treatment for cancer
WO2019030759A1 (en) 2017-08-08 2019-02-14 Technology Innovation Momentum Fund (Israel) Limited Partnership CHLORAMPHENICOL-RESISTANT TRUNCATED PROTEIN AND USES THEREOF
IL253984A0 (en) 2017-08-14 2017-09-28 Yeda Res & Dev Immunotherapy against aranviruses that bind through transferrin receptor 1 (tfr1
US11619634B2 (en) 2017-08-21 2023-04-04 Savicell Diagnostic Ltd. Methods of diagnosing and treating lung cancer
US11692166B2 (en) 2017-08-23 2023-07-04 Technion Research & Development Foundation Limited Compositions and methods for improving alcohol tolerance in yeast
US20200270604A1 (en) 2017-09-19 2020-08-27 Tropic Biosciences UK Limited Modifying the specificity of non-coding rna molecules for silencing gene expression in eukaryotic cells
WO2019058376A1 (en) 2017-09-19 2019-03-28 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) BIRDS WITH GENOME EDITION
CN111565731B (zh) 2017-10-24 2024-03-08 达莉亚·伊兰妮 治疗缺血性疾病的方法
EP3706795A4 (en) 2017-11-09 2021-10-13 Pinteon Therapeutics Inc. METHODS AND COMPOSITIONS FOR GENERATING AND USING HUMANIZED CONFORMATION SPECIFIC PHOSPHORYLATED TAU ANTIBODIES
IL255664A0 (en) 2017-11-14 2017-12-31 Shachar Idit Hematopoietic stem cells with enhanced properties
BR112020010830A2 (pt) 2017-11-29 2020-11-10 Weedout Ltd. composições, kits e métodos para controlar erva daninha do gênero amaranthus
IL274979B2 (en) 2017-11-29 2024-07-01 Univ Ramot Methods for the prevention and treatment of neurogenic seizures
EP3716993A1 (en) 2017-12-03 2020-10-07 Yeda Research and Development Co. Ltd Treatment of an ischemic heart disease
EP3723785A1 (en) 2017-12-17 2020-10-21 Yeda Research and Development Co. Ltd Cop9 signalosome (csn) complex modulators and uses thereof
EP3731965A1 (en) 2017-12-28 2020-11-04 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Method to reproduce circadian rhythms on a microfluidic chip
BR112020013238A2 (pt) 2017-12-29 2020-12-01 Cell Cure Neurosciences Ltd. composição e método para formular células do epitélio pigmentar da retina bem como uso da dita composição para tratar uma condição retiniana
US20210112739A1 (en) 2018-01-29 2021-04-22 Lavie Bio Ltd Plant microbial preparations, compositions and formulations comprising same and uses thereof
IL257225A (en) 2018-01-29 2018-04-09 Yeda Res & Dev Treatment of sarcoma
IL257269A (en) 2018-01-31 2018-04-09 Olender Tsviya Signaling is directed to the endoplasmic reticulum
EP3749368A1 (en) 2018-02-08 2020-12-16 Yeda Research and Development Co. Ltd Methods of identifying and using agents for treating diseases associated with intestinal barrier dysfunction
WO2019155459A1 (en) 2018-02-08 2019-08-15 Yeda Research And Development Co. Ltd. Inhibitors of the 20s proteasome
WO2019162945A1 (en) 2018-02-23 2019-08-29 Carmel Haifa University Economic Corporation Ltd. Methods for treating memory impairment and cognitive dysfunction
US20200408761A1 (en) 2018-02-28 2020-12-31 The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center Methods of diagnosing and treating bladder cancer
WO2019175869A1 (en) 2018-03-12 2019-09-19 Yeda Research And Development Co. Ltd Treatment of a heart disease
EP3765031A4 (en) 2018-03-14 2022-03-23 Memorial Sloan Kettering Cancer Center ANTI-POLYSIAL ACID ANTIBODIES AND USES THEREOF
US11648260B2 (en) 2018-03-29 2023-05-16 Technion Research And Development Foundation Limitted Vesicles comprising a PTEN inhibitor and uses of same
EP3774047A1 (en) 2018-03-29 2021-02-17 Yeda Research and Development Co. Ltd Use of electric field gradients to control gene expression
IL258467A (en) 2018-03-29 2018-07-04 Ilana Kolodkin Gal Methods of disrupting a biofilm and/or preventing formation of same
GB201807192D0 (en) 2018-05-01 2018-06-13 Tropic Biosciences Uk Ltd Compositions and methods for reducing caffeine content in coffee beans
IL259392A (en) 2018-05-15 2018-08-01 Yeda Res & Dev Vaccination with cancer neoantigens
WO2019220441A1 (en) 2018-05-15 2019-11-21 Hadasit Medical Research Services And Development Ltd. Compositions and methods for treating cancer resistant to an anti-cancer agent
EP3801614A1 (en) 2018-05-27 2021-04-14 BioLineRx Ltd. Agi-134 combined with a checkpoint inhibitor for the treatment of solid tumors
EP3785279A4 (en) 2018-05-31 2022-07-27 Immunity Pharma Ltd. COMPOSITIONS AND METHODS OF USE THEREOF IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
EP3802839A1 (en) 2018-06-07 2021-04-14 The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Center) Nucleic acid constructs and methods of using same
EP3800998A1 (en) 2018-06-07 2021-04-14 The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Center) Methods of regenerating and transforming cannabis
WO2020003311A1 (en) 2018-06-25 2020-01-02 Yeda Research And Development Co. Ltd. Systems and methods for increasing efficiency of genome editing
WO2020008412A1 (en) 2018-07-04 2020-01-09 Ukko Inc. Methods of de-epitoping wheat proteins and use of same for the treatment of celiac disease
EP3818529A2 (en) 2018-07-08 2021-05-12 Yeda Research and Development Co. Ltd Person-specific assessment of probiotics responsiveness
US12134638B2 (en) 2018-07-11 2024-11-05 Kahr Medical Ltd. SIRPalpha-4-1BBL variant fusion protein and methods of use thereof
SG11202012773QA (en) 2018-07-11 2021-01-28 Immunity Pharma Ltd Peptide compounds and therapeutic uses of same
AU2019315054A1 (en) 2018-07-31 2021-03-18 Collplant Ltd. Tobacco transgenic event and methods for detection and use thereof
IL261156A (en) 2018-08-14 2020-02-27 Fass Deborah Chimeric quiescin sulfhydryl oxidase (qsox1) antibodies and uses of same
EP3841201A1 (en) 2018-08-24 2021-06-30 Yeda Research and Development Co. Ltd Methods of modulating m2 macrophage polarization and use of same in therapy
WO2020058979A2 (en) 2018-09-20 2020-03-26 Yeda Research And Development Co. Ltd. Methods of treating amyotrophic lateral sclerosis
EP3856225A1 (en) 2018-09-25 2021-08-04 BioLineRx Ltd. Methods of selecting treatment for cxcr4-associated cancer
IL262658A (en) 2018-10-28 2020-04-30 Memorial Sloan Kettering Cancer Center Prevention of age related clonal hematopoiesis and diseases associated therewith
IL263184A (en) 2018-11-21 2020-05-31 Yarden Yosef Method of treating cancer and compositions for same
US12441776B2 (en) 2018-11-30 2025-10-14 Eirgen Pharma Ltd. Oxyntomodulin peptide analog formulations
US12478571B2 (en) 2018-12-17 2025-11-25 Pontis Biologics, Inc. Enzyme based compositions and methods for removing dental calculi
WO2020152686A1 (en) 2019-01-23 2020-07-30 Yeda Research And Development Co. Ltd. Culture media for pluripotent stem cells
SG11202107720UA (en) 2019-01-31 2021-08-30 Agency Science Tech & Res Cnx/erp57 inhibitor for use in the treatment or prevention of cancer
IL264768A (en) 2019-02-10 2020-08-31 Sagi Irit Anti-matrix metalloproteinase 7 (mmp-7) inhibitory antibody and uses thereof
IL264854A (en) 2019-02-14 2020-08-31 Bahat Anat Spt5 inhibitors and methods of use thereof
EP3927378A1 (en) 2019-02-21 2021-12-29 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Method for reduction drug-induced nephrotoxicity
EP3927807A1 (en) 2019-02-21 2021-12-29 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Methods of generating organoids for high throughput screening of drugs
IL286011B2 (en) 2019-03-05 2024-06-01 The State Of Israel Ministry Of Agriculture & Rural Development Agricultural Res Organization Aro Vo Genome-edited birds
EP3938400B1 (en) 2019-03-11 2025-07-30 Memorial Sloan Kettering Cancer Center Cd22 antibodies and methods of using the same
GB201903521D0 (en) 2019-03-14 2019-05-01 Tropic Biosciences Uk Ltd No title
GB201903519D0 (en) 2019-03-14 2019-05-01 Tropic Biosciences Uk Ltd Introducing silencing activity to dysfunctional rna molecules and modifying their specificity against a gene of interest
GB201903520D0 (en) 2019-03-14 2019-05-01 Tropic Biosciences Uk Ltd Modifying the specificity of non-coding rna molecules for silencing genes in eukaryotic cells
IL265486A (en) 2019-03-19 2020-09-30 Yeda Res & Dev Bistable type ii opsins and uses thereof
WO2020194317A1 (en) 2019-03-28 2020-10-01 Yeda Research And Development Co. Ltd. Method of treating lipid-related disorders
EP3946611A2 (en) 2019-03-31 2022-02-09 Yeda Research and Development Co. Ltd Anti-viral and anti-tumoral compounds
IL266433B (en) 2019-05-02 2020-11-30 Sagi Irit Preparations containing the propeptide of lysyl oxidase and their uses
EP3969619A1 (en) 2019-05-13 2022-03-23 Yeda Research and Development Co. Ltd Cell-free mirna biomarkers for prognosis and diagnosis of neurodegenerative diseases
IL266728B (en) 2019-05-19 2020-11-30 Yeda Res & Dev Identification of recurrent mutant neopeptides
JP7664856B2 (ja) 2019-05-22 2025-04-18 ハダシット メディカル リサーチ サービシーズ アンド ディベロップメント リミテッド ヒト多能性細胞を培養する方法
CA3140406A1 (en) 2019-05-28 2020-12-03 Shanghaitech University Composition and methods to treat ectodermal dysplasia 2, clouston type
AU2020291694B2 (en) 2019-06-12 2025-10-02 Hadasit Medical Research Services And Development Ltd. Methods of generating oligodendrocytes
EP3983540A1 (en) 2019-06-16 2022-04-20 Yeda Research and Development Co. Ltd Method for stabilizing intracellular rna
WO2020261281A1 (en) 2019-06-27 2020-12-30 Ramot At Tel-Aviv University Ltd. Semaphorin 3a antibodies and uses thereof
KR20220042139A (ko) 2019-07-04 2022-04-04 유코 아이엔씨. 에피토프 제거된 알파 글리아딘 및 복강병 및 글루텐 민감성의 관리를 위한 이의 용도
US20220267409A1 (en) 2019-07-11 2022-08-25 Kahr Medical Ltd. Heterodimers and methods of use thereof
US20220281960A1 (en) 2019-07-16 2022-09-08 Ramot At Tel-Aviv University Ltd. Compositions and methods for the treatment of tuberculosis
IL268111A (en) 2019-07-16 2021-01-31 Fainzilber Michael Methods of treating pain
EP4004548B1 (en) 2019-07-29 2026-01-14 Yeda Research and Development Co. Ltd Methods of treating and diagnosing lung cancer
US20220298522A1 (en) 2019-07-30 2022-09-22 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization Methods of controlling cannabinoid synthesis in plants or cells and plants and cells produced thereby
WO2021028909A1 (en) 2019-08-12 2021-02-18 Yeda Research And Development Co. Ltd. Dna repair blood test for predicting response of lung cancer patients to immunotherapy
US20240140988A1 (en) 2019-08-22 2024-05-02 Ariel Scientific Innovations Ltd. Scaled-up methods for purifying antibodies
EP4021463A1 (en) 2019-08-27 2022-07-06 Yeda Research and Development Co. Ltd Treatment of bacterial vaginosis
WO2021048852A1 (en) 2019-09-11 2021-03-18 Yeda Research And Development Co. Ltd. Methods of treating breast cancer
IL269674B (en) 2019-09-25 2020-08-31 Roy Bar Ziv Assembling protein complexes on a chip
WO2021070181A1 (en) 2019-10-08 2021-04-15 Nectin Therapeutics Ltd. Antibodies against the poliovirus receptor (pvr) and uses thereof
IL270306A (en) 2019-10-30 2021-05-31 Yeda Res & Dev Prevention and treatment of pre-myeloid and myeloid malignancies
WO2021084526A1 (en) 2019-10-31 2021-05-06 Yeda Research And Development Co. Ltd. Engineered autotrophic bacteria for co2 conversion to organic materials
BR112022009087A2 (pt) 2019-11-11 2022-07-26 Ibi Ag Innovative Bio Insecticides Ltd Nanocorpos para controle de insetos e usos dos mesmos
US12385054B2 (en) 2019-11-19 2025-08-12 Protalix Ltd. Removal of constructs from transformed cells
IL270800A (en) 2019-11-20 2021-05-31 Yeda Res & Dev A method for treating Alzheimer's disease
EP4077731A1 (en) 2019-12-22 2022-10-26 Yeda Research and Development Co. Ltd Diagnosis of frontotemporal dementia
IL271656A (en) 2019-12-22 2021-06-30 Yeda Res & Dev System and methods for identifying cells that have undergone genome editing
IL271778A (en) 2019-12-31 2021-06-30 Ichilov Tech Ltd Methods for treating atopic dermatitis
WO2021137231A1 (en) 2019-12-31 2021-07-08 Kahr Medical Ltd. Methods of culturing t cells with a 4-1bbl fusion polypeptide and uses of same
US20230048361A1 (en) 2019-12-31 2023-02-16 Kahr Medical Ltd. Methods of culturing t cells and uses of same
IL272074B2 (en) 2020-01-15 2024-12-01 Immunity Pharma Ltd Peptide compounds and methods of treating diseases using same
JP7685766B2 (ja) 2020-01-22 2025-05-30 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド 抗ide抗体およびその使用
IL272194A (en) 2020-01-22 2021-07-29 Yeda Res & Dev Multispecific antibodies for use in treating diseases
WO2021152584A1 (en) 2020-01-28 2021-08-05 Ariel Scientific Innovations Ltd. Methods of analyzing cell membranes
IL295179A (en) 2020-01-29 2022-09-01 Memed Diagnostics Ltd Methods for diagnosis and classification of viral infections
IL272389A (en) 2020-01-30 2021-08-31 Yeda Res & Dev Kits containing antibodies to PD-L1 and their uses in therapy
WO2021152587A1 (en) 2020-01-30 2021-08-05 Yeda Research And Development Co. Ltd. Treating acute liver disease with tlr-mik inhibitors
IL272390A (en) 2020-01-30 2021-08-31 Yeda Res & Dev Cancer treatment methods
WO2021152586A1 (en) 2020-01-30 2021-08-05 Yeda Research And Development Co. Ltd. Methods of analyzing microbiome, immunoglobulin profile and physiological state
CN115335532A (zh) 2020-02-09 2022-11-11 Nlc制药有限公司 Sars-cov-2快速检测测试
IL272586A (en) 2020-02-10 2021-08-31 Yeda Res & Dev A method for cell cluster analysis
EP4110823A1 (en) 2020-02-26 2023-01-04 A2 Biotherapeutics, Inc. Polypeptides targeting mage-a3 peptide-mhc complexes and methods of use thereof
US20230127559A1 (en) 2020-03-16 2023-04-27 Yeda Research And Development Co. Ltd. Peptide analogs and use of same in treating diseases, disorders or conditions associated with mutant p53 protein
KR20230003492A (ko) 2020-03-29 2023-01-06 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 고셔병 치료용 베타-글루코세레브로시다아제 변이체
WO2021199047A1 (en) 2020-03-31 2021-10-07 Biomuse Ltd. Bacteria for the prevention and treatment of smoke-induced lung damage
EP4133107A1 (en) 2020-04-06 2023-02-15 Yeda Research and Development Co. Ltd Methods of diagnosing cancer and predicting responsiveness to therapy
EP4132479A1 (en) 2020-04-07 2023-02-15 Ramot at Tel-Aviv University Ltd. Cannabidiol-containing compositions and uses thereof
CA3177360A1 (en) 2020-04-13 2021-10-21 Exoprother Medical Ltd. Cell-derived vesicles comprising wild-type p53 protein for antiviral therapy
US20210322483A1 (en) 2020-04-16 2021-10-21 Ichilov Tech Ltd. Cell-derived particles presenting heterologous cd24 and use thereof in therapy
WO2021229577A1 (en) 2020-05-12 2021-11-18 Collplant Ltd. Collagen as a delivery tool for metal-based anti-viral agents
IL274811B (en) 2020-05-20 2021-05-31 Yeda Res & Dev Spatial information is developed for the analysis of individual cells
IL298934A (en) 2020-06-10 2023-02-01 Univ Ramot Methods for identifying CpGs are implicated
WO2021260696A1 (en) 2020-06-22 2021-12-30 Ramot At Tel-Aviv University Ltd. Multi subunit protein modules, cells expressing same and uses thereof
US20230293530A1 (en) 2020-06-24 2023-09-21 Yeda Research And Development Co. Ltd. Agents for sensitizing solid tumors to treatment
IL276599A (en) 2020-08-09 2022-03-01 Yeda Res & Dev T cell receptor unique to mage-a1 and its uses
IL276627A (en) 2020-08-10 2022-03-01 Yeda Res & Dev Compositions for diagnosis and treatment of coronavirus infections
WO2022038539A2 (en) 2020-08-18 2022-02-24 Yeda Research And Development Co. Ltd. Anti-viral and anti-tumoral compounds
US20230309480A1 (en) 2020-08-18 2023-10-05 International Rice Research Institute Methods of increasing outcrossing rates in gramineae
IL277488A (en) 2020-09-21 2022-04-01 Yeda Res & Dev Weight regulation method
WO2022064494A2 (en) 2020-09-23 2022-03-31 Yeda Research And Development Co. Ltd. Methods and compositions for treating coronaviral infections
IL277743A (en) 2020-10-01 2022-04-01 Yeda Res & Dev A method for diagnosing breast cancer
EP4225902A1 (en) 2020-10-05 2023-08-16 Protalix Ltd. Dicer-like knock-out plant cells
CN116635056A (zh) 2020-10-07 2023-08-22 波塔力克斯有限公司 长效脱氧核糖核酸酶
WO2022079719A1 (en) 2020-10-15 2022-04-21 Yeda Research And Development Co. Ltd. Method of treating myeloid malignancies
IL278401A (en) 2020-10-29 2022-05-01 Yeda Res & Dev Polynucleotides for editing RNA and a method for using them
EP4240856A2 (en) 2020-11-09 2023-09-13 1E Therapeutics, Ltd. Catalytic sequence based methods of treating or preventing bacterial infections
AU2021387979A1 (en) 2020-11-26 2023-03-30 Ukko Inc. Modified high molecular weight glutenin subunit and uses thereof
IL279559A (en) 2020-12-17 2022-07-01 Yeda Res & Dev Controlling ubiquitination of mlkl for treatment of disease
EP4267741A2 (en) 2020-12-28 2023-11-01 1E Therapeutics, Ltd. P21 mrna target areas for silencing
WO2022144883A2 (en) 2020-12-28 2022-07-07 1E Therapeutics, Ltd. P21 mrna targeting dnazymes
AU2022206415A1 (en) 2021-01-10 2023-08-17 Supermeat The Essence Of Meat Ltd. Pluripotent stem cell aggregates and microtissues obtained therefrom for the cultured meat industry
US20240083843A1 (en) 2021-01-14 2024-03-14 Yeda Research And Development Co. Ltd. Methods of producing vitamin d
IL280340B (en) 2021-01-21 2022-04-01 Yeda Res & Dev Antibodies, peptides and combinations of same for the treatment or prevention of coronavirus infection
JP2024506954A (ja) 2021-02-18 2024-02-15 イェダ リサーチ アンド デベロップメント カンパニー リミテッド ワクチン作製用の遺伝子改変細菌
EP4294428A1 (en) 2021-02-18 2023-12-27 Yeda Research and Development Co. Ltd Method of generating vaccines
IL281561A (en) 2021-03-16 2022-10-01 Yeda Res & Dev Methods and devices for ex-utero mouse embryonic development
AU2022247325A1 (en) 2021-03-30 2023-10-05 Biomx Ltd. Pseudomonas bacteriophage and uses thereof
IL282188A (en) 2021-04-08 2022-11-01 Yeda Res & Dev Combined use of ketamine and bretigabine for the treatment of psychiatric disorders
WO2022238947A1 (en) 2021-05-12 2022-11-17 Biomx Ltd. Staphylococcus bacteriophage and uses thereof
IL283563A (en) 2021-05-30 2022-12-01 Yeda Res & Dev Profiling of amps for the diagnosis, monitoring and treatment of microbiome-related diseases
EP4352509A1 (en) 2021-06-06 2024-04-17 Yeda Research and Development Co. Ltd Combined treatment for cancer
WO2022264132A1 (en) 2021-06-13 2022-12-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method for reprogramming human cells
CR20240020A (es) 2021-06-16 2024-02-28 Seedx Tech Inc Métodos de clasificación de semillas de matthiola
NL2028466B1 (en) 2021-06-16 2022-12-21 Sakata Holland B V Methods of sorting matthiola seeds
EP4362662A1 (en) 2021-07-02 2024-05-08 Tropic Biosciences UK Limited Delay or prevention of browning in banana fruit
WO2023286059A1 (en) 2021-07-13 2023-01-19 Technion Research & Development Foundation Limited Compositions and methods for treating a medical condition
EP4373919A1 (en) 2021-07-18 2024-05-29 Gamida-Cell Ltd. Therapeutic nk cell populations
WO2023002492A1 (en) 2021-07-22 2023-01-26 Yeda Research And Development Co. Ltd. Codon optimization of nucleic acids
EP4380966A2 (en) 2021-08-03 2024-06-12 Genicity Limited Engineered tcr complex and methods of using same
EP4130028A1 (en) 2021-08-03 2023-02-08 Rhazes Therapeutics Ltd Engineered tcr complex and methods of using same
EP4384603A1 (en) 2021-08-10 2024-06-19 Gamida-Cell Ltd. Engineered nk cells, methods of their production and uses thereof
GB202112866D0 (en) 2021-09-09 2021-10-27 Tropic Biosciences Uk Ltd Resistance to fusarium wilt in a banana
GB202112865D0 (en) 2021-09-09 2021-10-27 Tropic Biosciences Uk Ltd Resistance to black sigatoka disease in banana
IL286430A (en) 2021-09-14 2023-04-01 Yeda Res & Dev Multispecific antibodies for use in the treatment of diseases
CN118696122A (zh) 2021-12-08 2024-09-24 耶达研究及发展有限公司 用于肺再生的多能肺祖细胞
EP4499108A1 (en) 2022-04-25 2025-02-05 Yeda Research and Development Co. Ltd Compositions for altering cyclic adp-ribose secondary messenger signalling
WO2025150045A1 (en) 2024-01-12 2025-07-17 Gabriel Nussbaum Bacterial targets, therapeutics, compositions, kits and methods of use in treating and/or preventing cancer
WO2026058262A1 (en) 2024-09-16 2026-03-19 Esther Priel Substituted tri-phenyl derivative compounds, compositions comprising same and applications of same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3654090A (en) * 1968-09-24 1972-04-04 Organon Method for the determination of antigens and antibodies
US3652761A (en) * 1969-09-04 1972-03-28 Corning Glass Works Immunochemical composites and antigen or antibody purification therewith

Also Published As

Publication number Publication date
CA964560A (en) 1975-03-18
BE777309A (nl) 1972-04-17
JPS58117455A (ja) 1983-07-13
CH557030A (de) 1974-12-13
JPS58117456A (ja) 1983-07-13
IL38371A0 (en) 1972-02-29
IL38371A (en) 1974-06-30
DE2164768A1 (de) 1972-07-20
NL7018838A (da) 1972-06-30
JPS5834783B1 (da) 1983-07-28
GB1348938A (en) 1974-03-27
AU3698671A (en) 1973-06-21
AU467394B2 (en) 1975-11-27
IT965020B (it) 1974-01-31
ZA718332B (en) 1972-09-27
SE398557B (sv) 1977-12-27
DK150690C (da) 1988-06-06
FR2120835A5 (da) 1972-08-18
EG11604A (en) 1977-08-15
AT320145B (de) 1975-01-27
BR7108553D0 (pt) 1973-07-03
ES398372A1 (es) 1975-06-16
NL154599B (nl) 1977-09-15
US3839153A (en) 1974-10-01
DE2164768B2 (de) 1976-01-22
FI54034C (fi) 1978-09-11
FI54034B (fi) 1978-05-31

Similar Documents

Publication Publication Date Title
DK150690B (da) Fremgangsmaade og analysepakke til bestemmelse af en komponent i reaktionen mellem et specifikt binder-protein og det tilsvarende bindelige stofved enzym-immunoanalyse
USRE31006E (en) Process for the demonstration and determination of reaction components having specific binding affinity for each other
Guesdon et al. The use of avidin-biotin interaction in immunoenzymatic techniques.
US4828985A (en) Antibodies against the complex of a small molecule and its binding protein, their preparation and their use in diagnostic methods
US3791932A (en) Process for the demonstration and determination of reaction components having specific binding affinity for each other
US4235960A (en) Competitive enzyme-linked immunoassay
USRE29169E (en) Process for the demonstration and determination of reaction components having specific binding affinity for each other
US4232001A (en) Methods and materials for detection of estrophilin
US4427781A (en) Particle agglutination immunoassay with agglutinator for determining haptens; PACIA
US4477576A (en) Antigen assay method and kit
US4621048A (en) Reagents containing an anti-ligand bound to an anti-enzyme and methods for employing said reagents in an immunoassy
HOSODA et al. Effect of bridge heterologous combination on sensitivity in enzyme immunoassay for cortisol
EP0383313A2 (en) Reagent for immunoassay, and kit containing the same
US4693969A (en) Reagent for use in a sandwich solid-phase enzyme-immunoassay and process for employing same
EP0124366A2 (en) Method of measuring biological ligands
Mariotti et al. A new solid phase immunoradiometric assay for antithyroid microsomal antibody
US6555388B1 (en) Binding protein capture assay
US9891214B2 (en) Immunological assay method
JPH081436B2 (ja) 生物学的液体中の遊離リガンドの測定方法および測定用キット
JPH0731191B2 (ja) チログロブリンを使用する甲状腺ホルモンの免疫定量法
EP0554458B1 (en) Immunoassay and monoclonal antibody for determining diarrheal shellfish poisons
EP0338045B1 (en) Solid-phase non-separation enzyme assay
EP0152305A2 (en) Method of measuring biological ligand by utilising amylase
Abdul-Ahad et al. An enzyme-linked immunosorbent assay (ELISA) for bovine LH capable of monitoring fluctuations in baseline concentrations
Pratt et al. Specificity of immunoassays: II. Heterogeneity of specificity of antibodies in antisera used for steroid immunoassay and the selective blocking of less specific antibodies, including a new method for the measurement of immunoassay specificity